Author Index to Volume 40

Abarbanel JM, Lemberg T, Yaroslavski U, Grisaru N, Belmaker RH. Electrophysiological responses to transcranial magnetic stimulation in depression and schizophrenia, 148

Abraham G, Friedman RH, Verghese C. Osteoporosis demonstrated by dual energy X-ray absorptiometry in chronic schizophrenic patients, 430-corr

Adinoff B, Cantey Kiser JM, Martin PR, Linnoila M. Response of dehydroepiandrosterone to corticotropin-releasing hormone stimulation in alcohol-dependent subjects, 1305

Adler LA
See Eberstein S
See Flach KA
See Nagamoto HT

Adrien J. See Maudhuit C

Advenier C. See Spreux-Varoquaux O

Agam G. See Patishi Y

Ağargün MY, Kara H, Algün E, Şekeroglu R, Tarakçioğlu M. High cholesterol levels in patients with sleep panic, 1064

Ahn YM. See Jung HY

Akimoto H. See Fujimoto T

Al-Amin HA, Schwarzkopf SB. Effects of the PCP analog dizocilpine on sensory gating: potential relevance to clinical subtypes of schizophrenia, 744

Alavi A. See Harper Mozley L

Albert MS. See Marcel B

Alexander GE. See Goldman RG

Algün E. See Ağargün MY

Ali F. See Bassett AS

Allen PS. See Silverstone PH

Alper KR. See Prichep LS

Alpert JE. See Tedlow JR

Al-Shabbout M. See Williamson DE

Altamura AC. Hypothalamic-pituitary-adrenal axis in schizophrenia, 560-corr

Altemus M. See Keuler DJ

Altman S. See Smith GN

Amador XF. See Butler PD

Anderson ML. See Schenck CH

Anderson V. See Brewer WJ

Andreason PJ. See Weingartner H

Andreski P. See Breslau N

Angelin B. See Eriksson M

Angrist B. See Eberstein S

Ansseau M. See Hansenne M

Anthony JL. See Bell IR

Arinami T, Li L, Mitsushio H, Itokawa M, Hamaguchi H, Toru M. An insertion/deletion polymorphism in the angiotensin converting enzyme gene is associated with both brain substance P contents and affective disorders, 1122

Arnetoli G. See Pallanti S

Arolt V. See Rothermundt M

Aronowitz B. See Stein DJ

Asarnow RF. See Strandburg RJ

Attias J, Bleich A, Furman V, Zinger Y. Event-related potentials in post-traumatic stress disorder of combat origin, 373

Babai M. See Stip E

Bammert Adams J. See Cowley DS

Barash I. See Silver H

Barber Y. See Weizman R

Bar-haim N. See Cohen H

Barthélémy C. See Petit E

Bassett AS, Chow EWC, Bury A, Ali F, Haylock CAH, Smith GN, Lapointe JS, Honer WG. Increased head circumference in schizophrenia, 1173

Battaglia M. See Ferini-Strambi L

Bauer J. See Weyerbrock A

Baumgartner A, Volz H-P, Campos-Barros A, Stieglitz R- D, Mansmann U, Mackert A. Serum concentrations of thyroid hormones in patients with nonseasonal affective disorders during treatment with bright and dim light, 899

Beal M. See Lim KO

Beaulieu S. See Leyton M

Becker T. See Franzek E

Beckmann H. See Franzek E

Bélanger C. See Leyton M

Bell IR, Bootzin RR, Davis TP, Hau V, Ritenbaugh C, Johnson KA, Schwartz GE. Time-dependent sensitization of plasma beta-endorphin in community elderly with self- reported environmental chemical odor intolerance, 134

Bell IR, Bootzin RR, Ritenbaugh C, Wyatt JK, DeGiovanni G, Kulinovich T, Anthony JL, Kuo TF, Rider SP, Peterson JM, Schwartz GE, Johnson KA. A polysomnographic study of sleep disturbance in community elderly with self-reported environmental chemical odor intolerance, 123

Belle S. See Ganguli M

Bellodi L
See Ferini-Strambi L
See Smeraldi E

Belmaker RH
See Abarbanel JM
See Patishi Y

Benjamin J, Gershon ES. Genetic discoveries in human behavior: small effect genes loom large, 313-ed

Berger M
See Biber K
See Weyerbrock A

Bergmans R. See Maes M

© 1996 Society of Biological Psychiatry

0006-3223/96/$15.00
PII S0006-3223(96)00481-9

Berman ME. See Coccaro EF
Berrettini WH, Persico AM. Dopamine D2 receptor gene polymorphism and vulnerability to substance abuse in African Americans, 144
Bertella S. See Ferini-Strambi L
Bessler H. See Weizman R
Biber K, Walden J, Gebicke-Härter P, Berger M, van Calker D. Carbamazepine inhibits the potentiation by adenosine analogues of agonist induced inositolphosphate formation in hippocampal astrocyte cultures, 563
Bickford P. See Flach KA
Biggs L. See Loven DP
Bird G. See Persico AM
Birkett M. See Pande AC
Birmaher B
See Rao U
See Williamson DE
Bleich A. See Attias J
Blennow K. See Heilig M
Bobes MA, Lei ZX, Ibáñez S, Yi H, Valdes-Sosa M. Semantic matching of pictures in schizophrenia: a cross-cultural ERP study, 189
Boisoneau D. See Grossman R
Bolwig TG. See Dalby NO
Bondy B. See Botschev C
Bootzin RR. See Bell IR
Bosmans E. See Maes M
Boston PF, Dursun SM, Zafar R, Reveley MA. Serum cholesterol and treatment resistance in schizophrenia, 542
Bothua D. See Spreux-Varoquaux O
Botschev C, Bondy B, Hofmann M, Kircher T, Müller-Spahn F. B_2-receptor density on mononuclear blood cells in patients suffering from neuroleptic-induced akathisia (NIA), 203
Bouvy PF. See de Groot MH
Boyce P. See Mitchell P
Bracha HS. See Davis JO
Bradwejn J. See Koszycki D
Braff DL. See Cadenhead KS
Brené S. See Jönsson E
Breslau N, Chilcoat H, DelDotto J, Andreski P, Brown G. Low birth weight and neurocognitive status at six years of age, 389
Brewer WJ, Edwards J, Anderson V, Robinson T, Pantelis C. Neuropsychological, olfactory, and hygiene deficitis in men with negative symptom schizophrenia, 1021
Brion S. See Spreux-Varoquaux O
Brodaty H. See Mitchell P
Broersen LM, Heinsbroek RPW, de Bruin JPC, Olivier B. Effects of local application of dopaminergic drugs into, the medial prefrontal cortex of rats on latent inhibition, 1083
Brooks J. See Dilsaver SC
Brown G. See Breslau N
Brown WS. See Strandburg RJ
Browne D. See Louie AK
Bruder G. See Graae F
Brunner DP, Kräuchi K, Dijk D-J, Leonhardt G, Haug H-J, Wirz-Justice A. Sleep electroencephalogram in seasonal affective disorder and in control women: effects of midday light treatment and sleep deprivation, 485
Buitelaar JK. See Kemner C
Burmeister LA. See Ganguli M
Bury A. See Bassett AS
Butin B. See Weizman R
Butler PD, Harkavy-Friedman JM, Amador XF, Gorman JM. Backward masking in schizophrenia: relationship to medication status, neuropsychological functioning, and dopamine metabolism, 295

Cadenhead KS, Perry W, Braff DL. The relationship of information-processing deficits and clinical symptoms in schizotypal personality disorder, 853
Calogero AE. See Johnson EO
Camfferman G. See Kemner C
Campion D. See Dollfus S
Campos-Barros A. See Baumgartner A
Cannon TD. See Zorrilla E
Cantey Kiser JM. See Adinoff B
Canuso C. See De Leon J
Carroll BJ. See Krishnan KRR
Carter C, Robertson L, Nordahl T, Chaderjian M, Kraft L, O'Shora-Celaya L. Spatial working memory deficits and their relationship to negative symptoms in unmedicated schizophrenia patients, 930
Carter CS. See Johnson EO
Castellanos FX. See Jacobsen LK
Castro-Blanco D. See Graae F
Centorrino F. See Rabinowitz T
Chabot RJ, Serfontein G. Quantitative electroencephalographic profiles of children with attention deficit hyperactivity disorder, 951
Chaderjian M. See Carter C
Chastanet M. See Maudhuit C
Chen EYH, Lam LCW, Chen RYL, Nguyen DGH. Blink rate, neurocognitive impairments, and symptoms in schizophrenia, 597
Chen RYL. See Chen EYH
Chen Y-W. See Dilsaver SC
Cherpi C. See Petit E
Chevalier J-F. See Spreux-Varoquaux O
Chilcoat H. See Breslau N
Chiodera P. See Marchesi C
Chow EWC. See Bassett AS
Christensen JD. See Stoll AL
Chrousos GP. See Johnson EO
Clancy K. See Nierenberg AA
Clarke AS. See Coe CL
Clarke AS, Hedeker DR, Ebert MH, Schmidt DE, McKinney WT, Kraemer GW. Rearing experience and biogenic amine activity in infant rhesus monkeys, 338
Cloninger CR. See Nelson EC
Coccaro EF, Berman ME, Kavoussi RJ, Hauger RL. Relationship of prolactin response to d-fenfluramine to behavioral and questionnaire assessments of aggression in personality-disordered men, 157
Coe CL, Hou F-Y, Clarke AS. Fluoxetine treatment alters leukocyte trafficking in the intrathecal compartment of the young primate, 361
Cohen BM. See Stoll AL
Cohen H, Bar-haim N, Kotler M. Acute inositol induces anxiety in rats, 426
Cohen L. See Stein DJ
Coiro V. See Marchesi C
Comings DE, Muhleman D, Gysin R. Dopamine D_2 receptor (DRD2) gene and susceptibility to posttraumatic stress disorder: a study and replication, 368
Cook J. See Cowley DS
Cooke RG, Krüger S, Shugar G. Comparative evaluation of two self-report mania rating scales, 279
Corin E. See Leyton M
Cortadellas T. See Rosel Soria P
Cosgrave M, Tyrrell J, Dreja H, Hawi Z, Lawlor BA, Gill M. Lower frequency of apolipoprotein E4 allele in an "elderly" Down's

syndrome population, 811
Cowen PJ. See Williams JH
Cowley DS, Bammert Adams J, Pyke RE, Cook J, Zaccharias P, Wingerson D, Roy-Byrne PP. Effect of CI- 988, a cholecystokinin-B receptor antagonist, on lactate-induced panic, 550
Crocq M-A. See Jönsson E
Csernansky JG
See Lim KO
See Nelson EC

Dadvand M. See De Leon J
Dahl RE. See Rao U
Dahl RE. See Williamson DE
Dalby NO, Tønder N, Wolby DPD, West M, Finsen B, Bolwig TG. No loss of hippocampal hilar somatostatinergic neurons after repeated electroconvulsive shock: a combined stereological and in situ hybridization study, 54
d'Amato T. See Dollfus S
Dar DE. See Weizman R
Davidson D. See Swift RM
Davidson M
See Harvey PD
See Zemishlany Z
Davis JO, Bracha HS. Famine and schizophrenia: first-trimester malnutrition or second-trimester beriberi?, 1
Davis KL. See Harvey PD
Davis TP. See Bell IR
Daviss SR. See DiMartini AF
de Bruin JPC. See Broersen LM
De Bruyn A. See Souery D
DeCaria CM. See Stein DJ
DeGiovanni G. See Bell IR
de Groot MH, Nolen WA, Huijsman AM, Bouvy PF. Lateralized neuropsychological functioning in depressive patients before and after drug therapy, 1282
DeKosky ST. See Ganguli M
De la Fuente JM, Mendlewicz J. TRH stimulation and dexamethasone suppression in borderline personality disorder, 412
DelDotto J. See Breslau N
De Leon J, Dadvand M, Canuso C, Odom-White A, Stanilla J, Simpson GM. Polydipsia and water intoxication in a long-term psychiatric hospital, 28
Delvenne V, Goldman S, De Maertelaer V, Simon Y, Luxen A, Lotstra F. Brain hypometabolism of glucose in anorexia nervosa: normalization after weight gain, 761
De Maertelaer V
See Delvenne V
See Souery D
den Boer JA. See van Megen HJGM
Denda K. See Inoue T
Deng Z-L. See Ohara K
DeQuardo JR
See Goldman M
See Tandon R
de Rooij SEJA. See van Someren EJW
Desnyder R. See Maes M
Detre T. The ten commandments of psychiatric research, 675
Devous MD Sr. See Gullion CM
Diaferia G. See Smeraldi E
Dijk D-J. See Brunner DP
Dilsaver SC, Swann SC, Chen Y-W, Shoaib A, Brooks J, Krajewski KJ, Gruber N, Tsai Y. Treatment of bipolar depression with carbamazepine: results of an open study, 935
DiMartini AF, Trzepacz PT, Daviss SR. Prospective study of FK506 side effects: anxiety or akathisia?, 407
Djaldetti M. See Weizman R
Dobie DJ. See Peskind ER
Doder M. See Kostić VS
Dollfus S, Campion D, Vasse T, Preterre P, Laurent C, d'Amato T, Thibaut F, Mallet J, Petit M. Association study between dopamine D1, D2, D3, and D4 receptor genes and schizophrenia defined by several diagnostic systems, 419
Domino EF. Monoamine oxidase, tobacco smoking, and psychiatric disorders, 433-corr
Donnelly CL, McEvoy JP, Wilson WH, Narasimhachari N. A study of the potential confounding effects of diet, caffeine, nicotine and lorazepam on the stability of plasma and urinary homovanillic acid levels in patients with schizophrenia, 1218
Dor J. See Toren P
Doucette JT. See Morgenstern H
Dougherty D. See Sallee F
Doyle S. See Nader S
Dreja H. See Cosgrave M
Dursun SM. See Boston PF

Earnst KS, Kring AS, Kadar MA, Salem JE, Shepard DA, Loosen PT. Facial expression in schizophrenia, 556
Eberstein S, Adler LA, Angrist B. Nefazodone and akathisia, 798
Ebert MH. See Clarke AS
Eckardt MJ. See Weingartner H
Eckhoff D. See Rothermundt M
Edwards J. See Brewer WJ
Eklundh T
See Eriksson M
See Nordin C
Eldar S. See Toren P
Enns M, Peeling J, Sutherland GR. Hippocampal neurons are damaged by caffeine-augmented electroshock seizures, 642
Epperson CN, McDougle CJ, Price LH. Intranasal oxytocin in obsessive-compulsive disorder, 547
Epperson CN, McDougle CJ, Price LH. Intranasal oxytocin in trichotillomania, 559-corr
Eriksson M, Eklundh T, Sjöberg S, Angelin B, Nordin C. Cholesterol lowering and cerebrospinal fluid neurotransmitters: increased levels of the anxiogenic cholecystokinin-tetrapeptide during simvastatin administration to healthy male volunteers, 302
Erzegovesi S. See Smeraldi E

Fabian J. See Silverstone PH
Fabian JL. See Stip E
Fagioli LR. See Marcel B
Fallon JH. See Solbrig MV
Faustman WO. See Lim KO
Fava M
See Nierenberg AA
See Tedlow JR
Fechner-Bates S. See Pande AC
Feldman-Naim S
See Leibenluft E
See Ozaki N
Feldon J
See Weiner I
See Williams JH
Fell J. See Röschke J
Ferini-Strambi L, Bellodi L, Oldani A, Bertella S, Smirne S, Battaglia M. Cyclic alternating pattern of sleep electroencephalogram in patients with panic disorder, 225
Fernström V. See Nordin C
Fido AA. See Olusi SO
Filipović S. See Kostić VS
Fink M. Neuroleptic malignant syndrome and catatonia: one entity or two?,

432-corr (response)
Finsen B. See Dalby NO
Flach KA, Adler LE, Gerhardt GA, Miller C, Bickford P, MacGregor RJ. Sensory gating in a computer model of the CA3 neural network of the hippocampus, 1230
Flöhl W. See Franzek E
Folkerts M, Rosenthal L, Roehrs T, Krstevska S, Murlidhar A, Zorick F, Wittig R, Roth T. The reliability of the diagnostic features in patients with narcolepsy, 208
Frank C. See Röschke J
Frankenburg FR. See Rabinowitz T
Franzek E, Becker T, Hofmann E, Flöhl W, Stöber G, Beckmann H. Is computerized tomography ventricular abnormality related to cycloid psychosis?, 1255
Frazier JA. See Jacobsen LK
Freedman R. See Nagamoto HT
Friedman E. See Wang H-Y
Friedman RH. See Abraham G
Fujimoto A. See Inagaki T
Fujimoto T, Nakano T, Takano T, Takeuchi K, Yamada K, Fukuzako T, Akimoto H. Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia, 14
Fukuzako T. See Fujimoto T
Fuller Torrey E. See Vander Putten DM
Furman V. See Attias J

Gabbay FH. See Persico AM
Gailledreau J. See Spreux-Varoquaux O
Gangemi PF. See Pallanti S
Ganguli M, Burmeister LA, Seaberg EC, Belle S, DeKosky ST. Association between dementia and elevated TSH: a community-based study, 714
Garcia-Rill E. See Schenck CH
Gavish M. See Weizman R
Geaney DP. See Williams JH
Gebicke-Härter P. See Biber K
Geijer T. See Jönsson E
George MS, Ketter TA, Parekh PI, Herscovitch P, Post RM. Gender differences in regional cerebral blood flow during transient self-induced sadness or happiness, 859
Gerhardt GA. See Flach KA
Gershon ES. See Benjamin J
Giedd JN. See Jacobsen LK
Gilbertson MW. See Gurvits TV
Giles DE. See Rao U
Gill M. See Cosgrave M
Giller EL Jr. See Grossman R
Glazer WM. See Morgenstern H
Gold PW. See Johnson EO
Goldman D. See Ozaki N
Goldman M. See Tandon R
Goldman M, Tandon R, Taylor SF, DeQuardo JR, Shipley JE, Patel B, Reddig S, Jibson M. Dexamethasone nonsuppression and short rapid eye movement latency in schizophrenia: markers of an affective diathesis?, 927
Goldman RG, Alexander GE, Zemishlany Z, Mukherjee S, Sackeim H, Prohovnik I. Acute effects of haloperidol on cerebral cortex blood flow in normal and schizophrenic subjects, 604
Goldman S. See Delvenne V
Goldstein JM. See Woods BT
Gonzalez Moreno A. See Hansenne M
Gordon AG. Tricyclic-induced musical hallucinations, 309-corr
Gordon CT. See Jacobsen LK
Gorman JM. See Butler PD
Graae F, Tenke C, Bruder G, Rotheram M-J, Piacentini J, Castro-Blanco D, Leite P, Towey J. Abnormality of EEG alpha asymmetry in female adolescent suicide attempters, 706
Grecu LM. See Pallanti S
Greden JF. See Pande AC
Greenberg B. See Keuler DJ
Griez E. See Pols H
Griffith JM. See Nagamoto HT
Grimes JB, Labbate LA. Spontaneous orgasm with the combined use of bupropion and sertraline, 1184-corr
Grisaru N. See Abarbanel JM
Grossman R, Yehuda R, Boisoneau D, Schmeidler J, Giller EL Jr. Prolactin response to low-dose dexamethasone challenge in combat-exposed veterans with and without posttraumatic stress disorder and normal controls, 1100
Grözinger M. See Röschke J
Gruber N. See Dilsaver SC
Gullion CM, Devous MD Sr, Rush AJ. Effects of four normalizing methods on data analytic results in functional brain imaging, 1106
Gur RC
See Harper Mozley L
See Zorrilla E
Gurvits TV, Shenton ME, Hokama H, Ohta H, Lasko NB, Gilbertson MW, Orr SP, Kikinis R, Jolesz FA, McCarley RW, Pitman RK. Magnetic resonance imaging study of hippocampal volume in chronic, combat-related posttraumatic stress disorder, 1091
Gustavsson JP. See Jönsson E
Guthrie D. See Strandburg RJ
Guze B. See Quintana J
Gysin R. See Comings DE

Hadzi-Pavlovic D. See Mitchell P
Häfner H. See Hambrecht M
Hagebeuk EEO. See van Someren EJW
Hamaguchi H. See Arinami T
Hamakawa H. See Shioiri T
Hambrecht M, Häfner H. Substance abuse and the onset of schizophrenia, 1155
Hamburger SD. See Jacobsen LK
Hamon M. See Maudhuit C
Hanna GL, Ornitz EM, Hariharan M. Urinary epinephrine excretion during intelligence testing in attention- deficit hyperactivity disorder and normal boys, 553
Hansenne M, Pitchot W, Gonzalez Moreno A, Urcelay Zaldua I, Ansseau M. Suicidal behavior in depressive disorder: an event-related potential study, 116
Hanstock CC. See Silverstone PH
Hariharan M. See Hanna GL
Harkavy-Friedman JM. See Butler PD
Harper R. See Strandburg RJ
Harper Mozley L, Gur RC, Gur RE, Mozley PD, Alavi A. Relationships between berbal memory performance and the cerebral distribution of fluorodeoxyglucose in patients with schizophrenia, 443
Harris D. See Lim KO
Harvey PD, Davidson M, White L, Keefe RSE, Hirschowitz J, Mohs RC, Davis KL. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the Brief Psychiatric Rating Scale, 755
Haskett RF. See Pande AC
Hau V. See Bell IR
Haug H-J. See Brunner DP
Hauger RL. See Coccaro EF
Hauzer R. See Pols H
Hawi Z. See Cosgrave M
Haylock CAH. See Bassett AS
Hea RA. See Nagamoto HT
Hedeker DR. See Clarke AS

Heilig M, Månsson JE, Blennow K. Cerebrospinal fluid transmitter metabolites and atmospheric pressure, 683-corr (response)
Heinsbroek RPW. See Broersen LM
Henderson R. See Zubenko GS
Hérault J. See Petit E
Herman MM. See Knable MB
Hermesh H. See Weizman R
Herscovitch P. See George MS
Heuser I. See Lammers C-H
Hibbeln JR, Salem N Jr. Risks of cholesterol-lowering therapies, 686-corr
Hickie I. See Mitchell P
Higa J. See Strandburg RJ
Higley JD, Mehlman PT, Poland RE, Taub DM, Vickers J, Suomi SJ, Linnoila M. CFS testosterone and 5-HIAA correlate with different types of aggressive behavior: a primary model, 1067
Hijman R. See van Berckel BNM
Hirschowitz J. See Harvey PD
Hoff AL. See Lim KO
Hofmann E. See Franzek E
Hofmann M. See Botschev C
Hohagen F. See Weyerbrock A
Hokama H. See Gurvits TV
Hollander E
See Stein DJ
See Wong CM
Hommer DW
See Jacobsen LK
See Weingartner H
Honer WG
See Bassett AS
See Smith GN
Hong WL. See Jacobsen LK
Hou F-Y. See Coe CL
Huijsman AM. See de Groot MH
Humphries D. See Mathew RJ
Hyde TM. See Knable MB

Ibáñez S. See Bobes MA
Inagaki T, Shikimi T, Fujimoto A, Ishino H, Okunishi H, Takaori S. Changes in the ratio of urinary α1-microglobulin to ulinastatin levels in patients with psychiatric diseases, 800
Inbar D. See Toren P
Indra M. See Jirsa R
Inoue T, Tsuchiya K, Miura J, Sakakibara S, Denda K, Kasahara T, Koyama T. Bromocrpiptine treatment of tricyclic and heterocyclic antidepressant-resistant depression, 151
Inubushi T. See Shioiri T
Ishigaki T. See Ohara K
Ishino H. See Inagaki T
Itokawa M. See Arinami T
Iznak AF. See Mikhailova ES

Jääskeläinen IP, Näätänen R, Sillanaukee P. Effect of acute ethanol on auditory and visual event- related potentials: a review and reinterpretation, 284
Jacobsen LK, Hommer DW, Hong WL, Castellanos FX, Frazier JA, Giedd JN, Rapoport JL. Blink rate in childhood-onset schizophrenia: comparison with normal and attention-deficit hyperactivity disorder controls, 1222
Jacobsen LK, Hong WL, Hommer DW, Hamburger SD, Castellanos FX, Frazier JA, Giedd JN, Gordon CT, Karp BI, McKenna K, Rapoport JL. Smooth pursuit eye movements in childhood-onset schizophrenia: comparison with attention-deficit hyperactivity disorder, 1144
Jahjah N. See Silver H
James JF. See Loven DP
Javitt DC. Glycine therapy of schizophrenia, 684-corr
Jibson M
See Goldman M
See Tandon R
Jirsa R, Libiger J, Mohr P, Radil T, Indra M. Rhythmic finger-tapping task and fast segmentation of neural processing in schizophrenics, 1301
Joffe RT, Levitt AJ, Young LT. The thyroid, magnesium, and calcium in major depression, 428
John ER. See Prichep LS
Johnson EO, Kamilaris TC, Carter CS, Calogero AE, Gold PW, Chrousos GP. The biobehavioral consequences of psychogenic stress in a small, social primate(*Callithrix jacchus jacchus*), 317
Johnson KA. See Bell IR
Jolas T. See Maudhuit C
Jolesz FA. See Gurvits TV
Jones R. See Louie AK
Jönk L. See Rao ML
Jonker C. See van Someren EJW
Jónsdóttir TJ. See Stefánsson SB
Jönsson E, Brené S, Lindblad K, Sharara S, Sedvall G, Schalling M. Lack of expansion of cytosine adenine guanine trinucleotide repeat in the dentatorubral and pallidoluysian atrophy gene in Swedish schizophrenic patients, 228
Jönsson E, Sedvall G, Brené S, Gustavsson JP, Geijer T, Terenius L, Crocq M-A, Lannfelt L, Tylec A, Sokoloff P, Schwartz JC, Wiesel F-A. Dopamine-related genes and their relationships to monoamone metabolites in CSF, 1032
Joo YH. See Jung HY
Jouvent R. See Pierson A
Jung HY, Kang UG, Ahn YM, Joo YH, Park J-B, Kim YS. Induction of tetradecanoyl phorbol acetate-inducible (*TIS*) genes by electroconvulsive shock in rat brain, 503

Kadar MA. See Earnst KS
Kadewari RP. See Smith RC
Kahn RS. See van Berckel BNM
Kalso E. See Wahlbeck K
Kamilaris TC. See Johnson EO
Kando J. See Rabinowitz T
Kaneko S. See Ueno S-i
Kang UG. See Jung HY
Kaplan A. See Silver H
Kaplan BB. See Zubenko GS
Kara H. See Ağargün MY
Karp BI. See Jacobsen LK
Karp L. See Weizman R
Kasahara T. See Inoue T
Kato T. See Shioiri T
Kaufman J. See Rao U
Kavoussi RJ. See Coccaro EF
Keck PE Jr. See Strakowski SM
Keefe RSE. See Harvey PD
Kemner C, Verbaten MN, Koelega HS, Buitelaar JK, van der Gaag RJ, Camfferman G, van Engeland H. Event-related brain potentials in children with attention-deficit and hyperactivity disorder: effects of stimulus deviancy and task relevance in the visual and auditory modality, 522
Kennedy BP. See Lyoo IK
Kessler J. See Zorrilla E
Ketter TA. See George MS
Keuler DJ, Altemus M, Michelson D, Greenberg B, Murphy DL. Behavioral effects of naloxone infusion in obsessive-compulsive disorder, 154
Kidron R. See Weiner I
Kikinis R. See Gurvits TV

Kim JW, Kirkpatrick B. Social isolation in animal models of relevance to neuropsychiatric disorders, 918
Kim YS. See Jung HY
Kircher T. See Botschev C
Kirchner H. See Rothermundt M
Kirkpatrick B. See Kim JW
Klæning U. See Takei N
Klein E. See Shahal B
Kleinman JE. See Knable MB
Knable MB, Hyde TM, Murray AM, Herman MM, Kleinman JE. A postmortem study of frontal cortical dopamine D1 receptors in schizophrenics, psychiatric controls, and normal controls, 1191
Knight DL. See Krishnan KRR
Koelega HS. See Kemner C
Komaroff AL. See Marcel B
Kondo N. See Ohara K
Kondoh K. See Ueno S-i
Koob GF. See Solbrig MV
Kopala L. See Smith GN
Koren S. See Toren P
Kornish RJ II. See Marcel B
Koshiro K. See Ueno S-i
Kostić VS, Lečić D, Doder M, Marinković J, Filipović S. Prolactin and cortisol responses to fenfluramine in Parkinson's disease, 769
Koszycki D, Zacharko RM, Le Melledo J-M, Young SN, Bradwejn J. Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers, 648
Kotani Y. See Ueno S-i
Kotler M. See Cohen H
Kouri EM, Lukas SE, Mendelson JH. P300 assessment of opiate and cocaine users: effects of detoxification and buprenorphine treatment, 617
Kowalik S. See Prichep LS
Koyama T. See Inoue T
Kraemer GW. See Clarke AS
Kraft L. See Carter C
Krajewski KJ. See Dilsaver SC
Kramer GL. See Weiner MF
Kräuchi K. See Brunner DP
Kremer I. See Shahal B
Kring AS. See Earnst KS
Krishnan KRR, Tupler LA, Ritchie JC Jr, McDonald WM, Knight DL, Nemeroff CB, Carroll BJ. Apolipoprotein E-ϵ4 frequency in geriatric depression, 69
Krstevska S. See Folkerts M
Krüger S. See Cooke RG
Kulinovich T. See Bell IR
Kuo TF. See Bell IR
Kushnir M. See Silver H
Kuznetsov O. See Swift RM

Labbate LA. See Grimes JB
Lafer B. See Stoll AL
Lam LCW. See Chen EYH
Lammers C-H, Heuser I. Hypothalamic-pituitary-adrenal axis in schizophrenia, 561-corr (response)
Lannfelt L. See Jönsson E
Lannon RA. See Louie AK
Laor N
See Toren P
See Weizman R
Lapointe JS
See Bassett AS
See Smith GN
Lappalainen J. See Ozaki N
Larive AB. See Vander Putten DM
Larue S. See Leyton M
Lasko NB. See Gurvits TV
Laurent C. See Dollfus S
Lauterbach EC. Bipolar disorders, dystonia, and compulsion after dysfunction of the cerebellum, dentatorubrothalamic tract, and substantia nigra, 726
Lawlor BA. See Cosgrave M
Lečić D. See Kostić VS
Lee CK. See Lyoo IK
Lee HK. See Lyoo IK
Lei ZX. See Bobes MA
Leibenluft E, Feldman-Naim S, Turner EH, Schwartz PJ, Wehr TA. Salivary and plasma measures of dim light melatonin onset (DLMO) in patients with rapid cycling bipolar disorder, 731
Leite P. See Graae F
Lelord G. See Petit E
Lemberg T. See Abarbanel JM
Le Melledo J-M. See Koszycki D
Leonhardt G. See Brunner DP
Levengood RA. See Yehuda R
Levitt AJ. See Joffe RT
Lewis C. See Tandon R
Lewis TB. See Louie AK
Leyton M, Bélanger C, Martial J, Beaulieu S, Corin E, Pecknold J, Ng Ying Kin NMK, Meaney M, Thavundayil J, Larue S, Vasavan Nair NP. Cardiovascular, neuroendocrine, amd monoaminergic responses to psychological stressors: possible differences between remitted panic disorder patients and healthy controls, 353
Li L. See Arinami T
Libiger J. See Jirsa R
Lijzenga C. See van Someren EJW
Lim KO, Harris D, Beal M, Hoff AL, Minn K, Csernansky JG, Faustman WO, Marsh L, Sullivan EV, Pfefferbaum A. Gray matter deficits in young onset schizophrenia are independent of age of onset, 4
Lindblad K. See Jönsson E
Link C. See Stip E
Linnoila M
See Adinoff B
See Higley JD
Lipkin WI. See Solbrig MV
Lipp O. See Souery D
Little KY. See Loven DP
Liu J-C. See Ohara K
Loosen PT. See Earnst KS
Lotstra F. See Delvenne V
Louie AK, Lannon RA, Rutzick EA, Browne D, Lewis TB, Jones R. Clinical feature of cocaine-induced panic, 938
Loven DP, James JF, Biggs L, Little KY. Increased manganese superoxide dismutase activity in postmortem brain from neuroleptic-treated psychotic patients, 230
Lowe JV. See Mathew RJ
Lucca A. See Smeraldi E
Lukas SE. See Kouri EM
Lussier I. See Stip E
Luxen A. See Delvenne V
Lykouras L. See Markianos M
Lyoo IK, Noam GG, Lee CK, Lee HK, Kennedy BP, Renshaw PF. The corpus callosum and lateral ventricles in children with attention-deficit hyperactivity disorder: a brain magnetic resonance imaging study, 1060

MacEwan GW. See Smith GN
MacGregor RJ. See Flach KA
Mackert A. See Baumgartner A
Maeda K. See Sakai K
Maes M, Vandoolaeghe E, Ranjan R, Bosmans E, Van Gastel A, Bergmans R, Desnyder R. Increased serum soluble CD8 or suppressor/cytotoxic antigen concentrations in

depression: suppressive effects of glucocorticoids, 1273
Mahieu B. See Souery D
Mahowald MW. See Schenck CH
Mallet J. See Dollfus S
Mallinger AG. See Soares JC
Mann K. See Röschke J
Mansmann U. See Baumgartner A
Månsson JE. See Heilig M
Marcel B, Komaroff AL, Fagioli LR, Kornish RJ II, Albert MS. Cognitive deficits in patients with chronic fatigue syndrome, 535
Marchesi C, Silvestrini C, Ponari O, Volpi R, Chiodera P, Coiro V. Unreliability of TRH test but not dexamethasone suppression test as a marker of depression in chronic vasculopathic patients, 637
Marinković J. See Kostić VS
Markianos M, Lykouras L, Stefanis C. Prolactin and TSH responses to TRH and to ECT in pre- and postmenopausal women with major depression, 403
Marsh JT. See Strandburg RJ
Marsh L. See Lim KO
Martial J. See Leyton M
Martin PR. See Adinoff B
Massi S. See Pallanti S
Matarazzo EB. Organic psychosis linked to chronic tonsillitis and subsequent encephalitis: a probable autoimmune process, 292
Mathew RJ. Postural syncope and autoregulation of cerebral blood flow, 923
Mathew RJ, Wilson WH, Lowe JV, Humphries D. Acute changes in cranial blood flow after cocaine hydrochloride, 609
Maudhuit C, Jolas T, Chastanet M, Hamon M, Adrien J. Reduced inhibitory potency of serotonin reuptake blockers on central serotonergic neurons in rats selectively deprived of rapid eye movement sleep, 1000
McCarley RW
See Gurvits TV
See Salisbury DF
McCook EC. See Slotkin TA
McCracken JT. See Rubin RT
McDonald WM. See Krishnan KRR
McDougle CJ. See Epperson CN
McEvoy JP. See Donnelly CL
McKenna K. See Jacobsen LK
McKinney WT. See Clarke AS
McRae KA. See Nagamoto HT
Meaney M. See Leyton M
Mecz L. See Shahal B
Mehlman PT. See Higley JD
Meijer J. See Pols H
Meinders AE. See Verkes RJ
Meistrich B. See Smith GN
Meltzer HY. See Ranjan R
Menchon JM. See Rosel Soria P
Mendelbaum K. See Souery D
Mendelson JH. See Kouri EM
Mendlewicz J
See De la Fuente JM
See Souery D, 305
Merkin H. See Prichep LS
Merril CR. See Vander Putten DM
Michelson D. See Keuler DJ
Mikhailova ES, Vladimirova TV, Iznak AF, Tsusulkovskaya EJ, Sushko NV. Abnormal recognition of facial expression of emotions in depressed patients with major depression disorder and schizotypal personality disorder, 697
Miller C. See Flach KA
Minn K. See Lim KO
Mirmiran M. See van Someren EJW
Mitchell P, Hadzi-Pavlovic D, Parker G, Hickie I, Wilhelm K, Brodaty H, Boyce P. Depressive psychomotor disturbance, cortisol, and dexamethasone, 941
Mitsushio H. See Arinami T
Miura J. See Inoue T
Miyasoto K. See Ohara K
Mizruhin A. See Silver H
Mohr P. See Jirsa R
Mohs RC. See Harvey PD
Moja EA. See Smeraldi E
Möller H-J. See Rao ML
Morgenstern H, Glazer WM, Doucette JT. Handedness and the risk of tardive dyskinesia, 35
Mortensen PB. See Takei N
Moss HB, Yao JK. Platelet dense granule secretion in adolescents with conduct disorder and substance abuse: preliminary evidence for variation in signal transduction, 892
Motohashi N. See Saito H
Mozley PD. See Harper Mozley L
Müh J-P. See Petit E
Muhleman D. See Comings DE
Mukherjee S. See Goldman RG
Müller-Spahn F. See Botschev C
Munitz H. See Weizman R
Munk-Jørgensen P. See Takei N
Murashita J. See Shioiri T
Murlidhar A. See Folkerts M
Murphy DL. See Keuler DJ
Murray AM
See Knable MB
See Takei N

Nääänen R. See Jääskeläinen IP
Nader S, Warner MD, Doyle S, Peabody CA. Euthyroid sick syndrome in psychiatric inpatients, 1288
Nagamoto HT, Adler LE, Hea RA, Griffith JM, McRae KA, Freedman R. Gating of auditory P50 in schizophrenics: unique effects of clozapine, 181
Nagase Y, Okubo Y, Toru M. Electroencephalography in schizophrenic patients: comparison between neuroleptic- naive state and after treatment, 452
Nakamura Y. See Ohara K
Nakano T. See Fujimoto T
Narasimhachari N. See Donnelly CL
Navarro MA. See Rosel Soria P
Nelson B. See Rao U
Nelson EC, Cloninger CR, Przybeck TR, Csernansky JG. Platelet serotonergic markers and tridimensional personality questionnaire measures in a clinical sample, 271
Nemeroff CB. See Krishnan KRR
Ng Ying Kin NMK. See Leyton M
Nguyen DGH. See Chen EYH
Nierenberg AA. See Tedlow JR
Nierenberg AA, Pava JA, Clancy K, Rosenbaum JF, Fava M. Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes?, 691
Nishida A. See Saito H
Noam GG. See Lyoo IK
Nolen WA. See de Groot MH
Nordahl T. See Carter C
Nordin C. See Eriksson M
Nordin C, Eklundh T. Cerebrospinal fluid transmitter metabolites and atmospheric pressure, 682-corr
Nordin C, Thysell Y, Eklundh T, Fernström V. Is post-lumbar-puncture headache influenced by the menstrual cycle?, 310-corr
Northoff G. Neuroleptic malignant syndrome and catatonia: one entity or two?, 431-corr
Notti I. See Weizman R

O'Callaghan E. See Takei N
Odnopozov N. See Silver H
Odom-White A. See De Leon J
Ohara K. See Ohara K
Ohara K, Nakamura Y, Xie D-W, Ishigaki T, Deng Z-L, Tani K, Zhang H-Y, Kondo N, Liu J-C, Miyasoto K, Ohara K. Polymorphisms of dopamine D2-like (D2, D3, and D4) receptors in schizophrenia, 1209
Ohta H. See Gurvits TV
Okubo Y. See Nagase Y
Okunishi H. See Inagaki T
Okuyama S. See Sakai K
Oldani A. See Ferini-Strambi L
Olivier B. See Broersen LM
Olusi SO, Fido AA. Serum Lipid concentrations in patient with major depressive disorder, 1128
Ornitz EM. See Hanna GL
Oros M. See Rosel Soria P
Orr SP. See Gurvits TV
O'Shora-Celaya L. See Carter C
Otani K. See Ueno S-i
Ozaki N, Rosenthal NE, Pesonen U, Lappalainen J, Feldman-Naim S, Schwartz PJ, Turner EH, Goldman D. Two naturally occurring amino acid substitutions of the 5- HT_{2A} receptor: similar prevalence in patients with seasonal affective disorder, 1267

Pallanti S, Grecu LM, Gangemi PF, Massi S, Parigi A, Arnetoli G, Quercioli L, Zaccara G. Smooth-pursuit eye movement and saccadic intrusions in obsessive-compulsive disorder, 1164
Pande AC, Birkett M, Fechner-Bates S, Haskett RF, Greden JF. Fluoxetine versus phenelzine in atypical depression, 1017
Pantelis C. See Brewer WJ
Papassotiropoulos A. See Rao ML
Parekh PI. See George MS
Parigi A. See Pallanti S
Park J-B. See Jung HY
Parker G. See Mitchell P
Partiot A. See Pierson A
Pascualy M. See Peskind ER
Patel B. See Goldman M
Patishi Y, Belmaker RH, Agam G. Effect of age, sex steroids, brain region, and genetic strain on brain inositol monophosphatase activity, 656
Pava JA. See Nierenberg AA
Pays M. See Spreux-Varoquaux O
Peabody CA. See Nader S
Pecknold J. See Leyton M
Peeling J. See Enns M
Pelzer E. See Rao ML
Perrot A. See Petit E
Perry W. See Cadenhead KS
Persico AM. See Berrettini WH
Persico AM, Bird G, Gabbay FH, Uhl GR. D_2 dopamine receptor gene *Taq*I A1 and B1 restruction fragment length polymorphisms: enhanced frequencies in psychostimulant-preferring polysubstance abusers, 776
Peskind ER, Raskind MA, Wingerson D, Pascualy M, Thal LJ, Dobie DJ, Wilkinson CW. Hypothalamic-pituitary- adrenocortical axis responses to physostigmine: effects of Alzheimer's Disease and gender, 61
Pesonen U. See Ozaki N
Peterson JM. See Bell IR
Petit E, Hérault J, Raynaud M, Cherpi C, Perrot A, Barthélémy C, Lelord G, Müh J-P. X chromosome and infantile autism, 457
Petit M. See Dollfus S
Petty F. See Weiner MF
Pfefferbaum A. See Lim KO
Phillips JJ. See Rubin RT
Piacentini J. See Graae F
Piel E. See Shahal B
Pierson A, Ragot R, Van Hooff J, Partiot A, Renault B, Jouvent R. Heterogeneity of information-processing alterations according to dimensions of depression: an event-related potentials study, 98
Pijl H. See Verkes RJ
Pitchot W. See Hansenne M
Pitman RK. See Gurvits TV
Plas J. See Spreux-Varoquaux O
Poland RE. See Higley JD
Pols H, Verburg K, Hauzer R, Meijer J, Griez E. Alprazolam premedication and 35 carbon dioxide vulnerability in panic patients, 913
Ponari O. See Marchesi C
Post RM. See George MS
Pot A-M. See van Someren EJW
Prentice-Cuntz T. See Röschke J
Preterre P. See Dollfus S
Price LH. See Epperson CN
Prichep LS, Alper KR, Kowalik S, Merkin H, Tom ML, John ER, Rosenthal MS. Quantitative electroencephalographic characteristics of crack concaine dependence, 986
Prien RF, Rush AJ. National Institute of Mental Health workshop report on the treatment of bipolar disorder, 215
Prohovnik I. See Goldman RG
Przybeck TR. See Nelson EC
Pyke RE. See Cowley DS

Quercioli L. See Pallanti S
Quintana J, Shah B, Guze B. Clozapine-chlorpromazine allergic cross-reactivity in a psychotic patient with asymptomatic AIDS, 1186-corr

Rabinowitz T, Frankenburg FR, Centorrino F, Kando J. The effect of clozapine on saliva flow rate: a pilot study, 1132
Radil T. See Jirsa R
Ragot R. See Pierson A
Ranjan R. See Maes M
Ranjan R, Meltzer HY. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression, 253
Rao ML, Pelzer E, Papassotiropoulos A, Tiemeier H, Jönk L, Möller H-J. Selective slow- wave sleep deprivation influences blood serotonin profiles and serum melatonin concentrations in healthy subjects, 664
Rao R. See Rao U
Rao U, Dahl RE, Ryan ND, Birmaher B, Williamson DE, Giles DE, Rao R, Kaufman J, Nelson B. The relationship between longitudinal clinical course and sleep and cortisol changes in adolescent depression, 474
Rapoport JL. See Jacobsen LK
Raskind MA. See Peskind ER
Rawlings RR. See Weingartner H
Rawlins JNP. See Williams JH
Raynaud M. See Petit E
Reddig S. See Goldman M
Rehavi M. See Toren P
Reid S. See Solbrig MV
Reiss A. See Toren P
Reite M, Teale P, Sheeder J, Rojas DC, Schneider EE. Magnetoencephalographic evidence of abnormal early auditory memory

function in schizophrenia, 299
Renault B. See Pierson A
Renshaw PF
See Lyoo IK
See Stoll AL
Reveley MA. See Boston PF
Rider SP. See Bell IR
Rimón R. See Wahlbeck K
Rio DE. See Weingartner H
Risser RC. See Weiner MF
Ritchie JC. See Slotkin TA
Ritchie JC Jr. See Krishnan KRR
Ritenbaugh C. See Bell IR
Robertson L. See Carter C
Robinson T. See Brewer WJ
Roehrs T. See Folkerts M
Rojas DC. See Reite M
Röschke J, Prentice-Cuntz T, Wagner P, Mann K, Frank C. Amplitude frequency characteristics of evoked potentials during sleep: an analysis of the brain's transfer properties in depres, 736
Röschke J, Wagner P, Mann K, Fell J, Grözinger M, Frank C. Single trial analysis of event related potentials: a comparison between schizophrenics and depressives, 844
Rosel Soria P, Vallejo J, Oros M, Menchon JM, Cortadellas T, Navarro MA, Urretavizcaya M. Seasonal variability in blood platelet 3H-imipramine binding in healthy controls: age and gender effects, 981
Rosen J. See Zubenko GS, 1008
Rosenbaum JF
See Nierenberg AA
See Tedlow JR
Rosenthal L. See Folkerts M
Rosenthal MS. See Prichep LS
Rosenthal NE. See Ozaki N
Roth T. See Folkerts M
Rotheram M-J. See Graae F
Rothermundt M, Arolt V, Weitzsch C, Eckhoff D, Kirchner H. Production of cytokines in acute schizophrenic psychosis, 1294
Roy-Byrne PP. See Cowley DS
Rubin RT, Phillips JJ, McCracken JT, Sadow TF. Adrenal gland volume in major depression: relationship to basal and stimulated pituitary-adrenal cortical axis function, 89
Rush AJ
See Gullion CM
See Prien RF
Ruttimann UE. See Weingartner H
Rutzick EA. See Louie AK
Ryan ND
See Rao U
See Williamson DE

Sachs GS. See Stoll AL
Sackeim H. See Goldman RG
Sadow TF. See Rubin RT
Saito H, Nishida A, Shimizu M, Motohashi N, Yamawaki S. Decreased inositol 1,4,5-triphosphate-specific binding in platelets from alcoholic subjects, 886
Sakai K, Maeda K, Okuyama S, Tanaka C. Phencyclidine alters regional concentrations of neuropeptide Y and peptide YY in rat brain, 1246
Sakakibara S. See Inoue T
Salem JE. See Earnst KS
Salem N Jr. See Hibbeln JR
Salisbury DF, Voglmaier MM, Seidman LJ, McCarley RW. Topographic abnormalities of P3 in schizotypal personality disorder, 165
Sallee F, Dougherty D, Sethuraman G, Vrindavanam N. Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette's syndrome, 1044
Sano A. See Ueno S-i
Sax KW. See Strakowski SM
Schalling M. See Jönsson E
Scheltens P. See van Someren EJW
Schenck CH, Garcia-Rill E, Skinner RD, Anderson ML, Mahowald MW. A case of REM sleep behavior disorder with autopsy-confirmed Alzheimer's disease: postmortem brain stem histochemical analyses, 422
Schmeidler J. See Grossman R
Schmidt DE. See Clarke AS
Schneider EE. See Reite M
Schwartz GE. See Bell IR
Schwartz JC. See Jönsson E
Schwartz PJ
See Leibenluft E
See Ozaki N
Schwarzkopf SB. See Al-Amin HA
Sczekan SR, Strumwasser F. Antipsychotic drugs block IP_3-dependent Ca^{2+}-release from rat brain microsomes, 497
Seaberg EC. See Ganguli M
Sedvall G. See Jönsson E
Seidler FJ. See Slotkin TA
Seidman LJ
See Salisbury DF
See Woods BT
Şekeroglu R. See Ağargün MY
Sela B-A. See Toren P
Serfontein G. See Chabot RJ
Sethuraman G. See Sallee F
Setters MJ. See Strakowski SM
Shadach E. See Weiner I
Shah B. See Quintana J
Shahal B, Piel E, Mecz L, Kremer I, Klein E. Lack of advantage for imipramine combined with lithium versus imipramine alone in the treatment of major depression—a double-blind controlled study, 1181
Sham PC. See Takei N
Sharara S. See Jönsson E
Shaw NA. The effects of electroconvulsive shock on the thalamic auditory potential, 807
Sheeder J. See Reite M
Shenton ME. See Gurvits TV
Shepard DA. See Earnst KS
Shikimi T. See Inagaki T7
Shimizu M. See Saito H
Shioiri T, Kato T, Murashita J, Hamakawa H, Inubushi T, Takahashi S. High-energy phosphate metabolism in the frontal lobes of patients with panic disorder detected by phase-encoded ^{31}P-MRS, 785
Shipley JE
See Goldman M
See Tandon R
Shoaib A. See Dilsaver SC
Shugar G. See Cooke RG
Siever LJ. See Yehuda R
Sillanaukee P. See Jääskeläinen IP
Silver H, Barash I, Odnopozov N, Jahjah N, Mizruhin A. Melatonin secretion during fluvoxamine treatment in medicated chronic schizophrenic patients: evidence for the development of tolerance to selective serotonin re-uptake inhibitor, 75
Silver H, Kushnir M, Kaplan A. Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study, 671
Silverstone PH, Hanstock CC, Fabian J, Staab R, Allen PS. Chronic lithium does not alter human *myo*- inositol or phosphomonoester concentrations as measured by ^{1}H and ^{31}P MRS,

235
Silvestrini C. See Marchesi C
Simeon D. See Stein DJ
Simon Y. See Delvenne V
Simpson GM. See De Leon J
Sirocco KY. See Weingartner H
Sjöberg S. See Eriksson M
Skinner RD. See Schenck CH
Slotkin TA, McCook EC, Ritchie JC, Seidler FJ. Do glucocorticoids contribute to the abnormalities in serotonin transporter expression and function seen in depression? An animal model, 576
Smeraldi E, Diaferia G, Erzegovesi S, Lucca A, Bellodi L, Moja EA. Tryptophan depletion in obsessive-compulsive patients, 398
Smirne S. See Ferini-Strambi L
Smith GN. See Bassett AS
Smith GN, MacEwan GW, Altman S, Meistrich B, Lapointe JS, Kopala L, Honer WG. Obstetric complications and age- related changes in brain morphology in schizophrenia, 1200
Smith RC, Kadewari RP. Neurological soft signs and response to risperidone in chronic schizophrenia, 1056
Soares JC, Mallinger AG. Abnormal phosphatidylinositol (PI)-signalling in bipolar disorder (erratum), 78
Sokoloff P. See Jönsson E
Solbrig MV, Koob GF, Fallon JH, Reid S, Lipkin WI. Prefrontal cortex dysfunction in Borna disease virus (BDV)-infected rats, 629
Souery D, Lipp O, Mahieu B, Mendelbaum K, De Bruyn A, De Maertelaer V, Van Broeckhoven C, Mendlewicz J. Excess tyrosine hydroxylase restriction fragment length polymorphism homozygosity in unipolar but not bipolar patients: a preliminary report, 305
Speciale SG. See Weiner MF
Spreux-Varoquaux O, Gailledreau J, Vanier B, Bothua D, Plas J, Chevalier J-F, Advenier C, Pays M, Brion S. Initial increase of plasma serotonin: a biological predictor for the antidepressant response to clomipramine?, 465
Staab R. See Silverstone PH
Stabler S. See Zubenko GS
Stanilla J. See De Leon J
Stefanis C. See Markianos M
Stefánsson SB, Jónsdóttir TJ. Auditory event-related potentials, auditory digit span, and clinical symptoms in chronic schizophrenic men on neuroleptic medication, 19
Stein DJ, Hollander E, DeCaria CM, Simeon D, Cohen L, Aronowitz B. m-Chlorophenylpiperazine challenge in borderline personality disorder: relationship of neuroendocrine response, behavioral response, and clinical measures, 508
Stieglitz R-D. See Baumgartner A
Stiffler JS. See Zubenko GS
Stip E, Lussier I, Babai M, Fabian JL, Link C. Seroquel and cognitive improvement in patients with schizophrenia, 434-corr
Stöber G. See Franzek E
Stoll AL, Sachs GS, Cohen BM, Lafer B, Christensen JD, Renshaw PF. Choline in the treatment of rapid-cycling polar disorder: Clinical and neurochemical findings in lithium-treated patients, 382
Strakowski SM, Sax KW, Setters MJ, Keck PE Jr. Enhanced response to repeated d-amphetamine challenge: evidence for behavioral sensitization in humans, 872
Strandburg RJ, Marsh JT, Brown WS, Asarnow RF, Higa J, Harper R, Guthrie D. Continuous-processing-related event-related potentials in children with attention- deficit hyperactivity disorder, 964
Strange PG. See Vile JM
Strumwasser F. See Sczekan SR
Sullivan EV. See Lim KO
Sundblom M. See Wahlbeck K
Suomi SJ. See Higley JD
Sushko NV. See Mikhailova ES
Sutherland GR. See Enns M
Swaab DF. See van Someren EJW
Swann SC. See Dilsaver SC
Swift RM, Davidson D, Whelihan W, Kuznetsov O. Ondansetron alters human alcohol intoxication, 514

Takahashi S. See Shioiri T
Takano T. See Fujimoto T
Takaori S. See Inagaki T
Takei N, Mortensen PB, Klæning U, Murray RM, Sham PC, O'Callaghan E, Munk- Jørgensen P. Relationship between in utero exposure to influenza epidemics and risk of schizophrenia in Denmark, 817
Takeuchi K. See Fujimoto T
Tanaka C. See Sakai K
Tandon R. See Goldman M
Tandon R, Lewis C, Taylor SF, Shipley JE, DeQuardo JR, Jibson M, Goldman M. Relationship between DST nonsuppression and shortened REM latency in schizophrenia, 660
Tani K. See Ohara K
Tarakçioğlu M. See Ağargün MY
Tarrasch R. See Weiner I
Taub DM. See Higley JD
Taylor SF
See Goldman M
See Tandon R
Teale P. See Reite M
Tedlow JR, Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Rosenbaum JF. Are study dropouts different from completers?, 668
Teicher MH. See Yehuda R
Tenke C. See Graae F
Terao T. Tricyclic-induced musical hallucinations, 310-corr (response)
Terenius L. See Jönsson E
Thal LJ. See Peskind ER
Thavundayil J. See Leyton M
Thibaut F. See Dollfus S
Thysell Y. See Nordin C
Tiemeier H. See Rao ML
Tigerstedt I. See Wahlbeck K
Timmer J. See Weyerbrock A
Tom ML. See Prichep LS
Tølnder N. See Dalby NO
Toren P, Dor J, Rehavi M, Weizman A. Hypothalamic- pituitary-ovarian axis and mood, 1051
Toren P, Eldar S, Sela B-A, Wolmer L, Weitz R, Inbar D, Koren S, Reiss A, Weizman R, Laor N. Zinc deficiency in attention-deficit hyperactivity disorder, 1308
Toru M
See Arinami T
See Nagase Y
Towey J. See Graae F
Trestman RL. See Yehuda R
Trzepacz PT. See DiMartini AF
Tsai Y. See Dilsaver SC
Tsuang MT. See Woods BT
Tsuchiya K. See Inoue T
Tsusulkovskaya EJ. See Mikhailova ES
Tupler LA. See Krishnan KRR
Turner EH

See Leibenluft E
See Ozaki N
Tylec A. See Jönsson E
Tyrrell J. See Cosgrave M

Uebelacker LA. See Tedlow JR
Ueno S-i, Otani K, Kaneko S, Koshiro K, Kondoh K, Kotani Y, Sano A. Cytochrome P-450 2D6 gene polymorphism is not associated with neuroleptic malignant syndrome, 72
Uhl GR. See Persico AM
Urcelay Zaldua I. See Hansenne M
Urretavizcaya M. See Rosel Soria P

Valdes-Sosa M. See Bobes MA
Vallejo J. See Rosel Soria P
van Berckel BNM, Hijman R, van der Linden JA, Westenberg HGM, van Ree JM, Kahn RS. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients, 1298
Van Broeckhoven C. See Souery D
van Calker D. See Biber K
van der Gaag RJ. See Kemner C
van der Linden JA. See van Berckel BNM
Vander Putten DM, Fuller Torrey E, Larive AB, Merril CR. Plasma protein variations in monozygotic twins discordant for schizophrenia, 437
Vandoolaeghe E. See Maes M
van Engeland H. See Kemner C
Van Gastel A. See Maes M
Van Hooff J. See Pierson A
Vanier B. See Spreux-Varoquaux O
Van Kempen GMJ. See Verkes RJ
van Megen HJGM, Westenberg HGM, den Boer JA. Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients, 804
van Ree JM. See van Berckel BNM
van Someren EJW, Hagebeuk EEO, Lijzenga C, Scheltens P, de Rooij SEJA, Jonker C, Pot A-M, Mirmiran M, Swaab DF. Circadian rest-activity rhythm disturbances in Alzheimer's disease, 259
Vasavan Nair NP. See Leyton M
Vasse T. See Dollfus S
Verbaten MN. See Kemner C
Verburg K. See Pols H
Verghese C. See Abraham G
Verkes RJ, Pijl H, Meinders AE, Van Kempen GMJ. Borderline personality, impulsiveness, and platelet monoamine measures in bulimia nervosa and recurrent suicidal behavior, 173
Vickers J. See Higley JD
Vile JM, Strange PG. D2-like dopamine receptors are not detectable on human peripheral blood lymphocytes, 881
Vladimirova TV. See Mikhailova ES
Voglmaier MM. See Salisbury DF
Volpi R. See Marchesi C
Volz H-P. See Baumgartner A
Vrindavanam N. See Sallee F

Wagner P. See Röschke J
Wahlbeck K, Sundblom M, Kalso E, Tigerstedt I, Rimón R. Elevated plasma vasopressin and normal cerebrospinal fluid angiotensin-converting enzyme in chronic pain disorder, 994
Walden J. See Biber K
Wang H-Y, Friedman E. Enhanced protein kinase C activity and translocation in bipolar affective disorder brains, 568
Warner MD. See Nader S
Waziri R. Glycine therapy of schizophrenia, 685-corr (response)
Wehr TA. See Leibenluft E
Weiner I, Shadach E, Tarrasch R, Kidron R, Feldon J. The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine, 834
Weiner MF, Speciale SG, Risser RC, Kramer GL, Petty F. Cerebrospinal fluid and plasma gamma-aminobutyric acid in Alzheimers disease, 933
Weingartner H, Andreason PJ, Hommer DW, Sirocco KY, Rio DE, Ruttimann UE, Rawlings RR, Eckardt MJ. Monitoring the source of memory in detoxified alcoholics, 43
Weitz R. See Toren P
Weitzsch C. See Rothermundt M
Weizman A. See Toren P
Weizman R. See Toren P
Weizman R, Karp L, Dar DE, Butin B, Hermesh H, Munitz H, Gavish M. Electroconvulsive therapy down-regulates platelet peripheral-type benzodiazepine receptors in medication-resistant major depressed patients, 221
Weizman R, Laor N, Barber Y, Hermesh H, Notti I, Djaldetti M, Bessler H. Cytokine production in obsessive-compulsive disorder, 908
Wellman NA. See Williams JH
West M. See Dalby NO
Westenberg HGM
See van Berckel BNM
See van Megen HJGM
Weyerbrock A, Timmer J, Hohagen F, Berger M, Bauer J. Effects of light and chronotherapy on human circadian rhythms in delayed sleep phase syndrome: cytokines, cortisol, growth hormone, and the sleep-wake cycle, 794
Whelihan W. See Swift RM
White L. See Harvey PD
Wiesel F-A. See Jönsson E
Wilhelm K. See Mitchell P
Wilkinson CW. See Peskind ER
Williams JH, Wellman NA, Geaney DP, Cowen PJ, Feldon J, Rawlins JNP. Antipsychotic drug effects in a model of schizophrenic attentional dksorder: a randomized controlled trial of the effects of haloperidol on latent inhibition in healthy people, 1135
Williamson DE. See Rao U, 474
Williamson DE, Birmaher B, Dahl RE, Al-Shabbout M, Ryan ND. Stressful life events influence nocturnal growth hormone secretion in depressed children, 1176
Wilson WH
See Donnelly CL
See Mathew RJ
Wingerson D
See Cowley DS
See Peskind ER
Wirz-Justice A. See Brunner DP
Wittig R. See Folkerts M
Wolby DPD. See Dalby NO
Wolmer L. See Toren P
Wong CM, Hollander E. Headache response to m-chlorophenylpiperazine in obsessive-compulsive disorder and normal controls, 544
Woods BT, Yurgelun-Todd D, Goldstein JM, Seidman LJ, Tsuang MT. MRI brain abnormalities in chronic schizophrenia: one process or more?, 585
Wyatt JK. See Bell IR

Xie D-W. See Ohara K

Yamada K. See Fujimoto T
Yamawaki S. See Saito H
Yao JK. See Moss HB
Yaroslavski U. See Abarbanel JM
Yehuda R. See Grossman R
Yehuda R, Teicher MH, Trestman RL, Levengood RA, Siever LJ. Cortisol regulation in posttraumatic stress disorder and major depression: a chronobiological analysis, 79
Yi H. See Bobes MA
Young LT. See Joffe RT
Young SN. See Koszycki D
Yurgelun-Todd D. See Woods BT

Zaccara G. See Pallanti S
Zaccharias P. See Cowley DS
Zacharko RM. See Koszycki D
Zafar R. See Boston PF
Zemishlany Z. See Goldman RG
Zemishlany Z, Davidson M. Lack of effect of laboratory-provoked anxiety on plasma homovanillic acid concentration in normal subjects, 247
Zhang H-Y. See Ohara K
Zinger Y. See Attias J
Zorick F. See Folkerts M
Zorrilla E, Cannon TD, Gur RE, Kessler J. Leukocytes and organ-nonspecific autoantibodies in schizophrenics and their siblings: markers of vulnerability or disease?, 825
Zubenko GS, Henderson R, Stiffler JS, Stabler S, Rosen J, Kaplan BB. Association of the *APOR*ϵ4 allele with clinical subtypes of late life depression, 1008

Subject Index to Volume 40

Absolute tissue
  brain, MRI in schizophrenia and, 585
Abstinence
  cocaine, quantitative EEG and, 986
Acetylcholine
  sensory gating in schizophrenia and, 1230
Acoustic startle reflex
  dizocilpine and, 744
Acquired immunodeficiency syndrome (AIDS)
  clozapine-chlorpromazine allergic cross-reactivity in psychosis and, 1186-corr
Actigraphy
  Alzheimer's disease and, 259
Activity level
  d-amphetamine challenge and, 872
Adenosine A_1 receptors
  carbamazepine and, 563
Adenosine diphosphate (ADP)
  conduct disorder and, 892
Adolescents
  conduct disorder in, 892
  depression in, 474
  platelet dense granule secretion in, 892
  substance abuse in, 892
  suicidal female, EEG alpha asymmetry in, 706
  Tourette's syndrome in, 1044
Adrenal gland
  volume, major depression and, 89
Adrenocorticotropic hormone (ACTH)
  acute tryptophan depletion and, 648
  adrenal gland volume in major depression and, 89
  biobehavioral consequences of social stress and, 317
Affect
  transient emotion and, 859
Affective diathesis
  markers of, 927
Affective disorders
  bromocriptine in, 151
  carbamazepine in, 563
  insertion/deletion polymorphism in angiotensin converting enzyme gene in, 1122
  α1-microglobulin in, 800
  protein kinase C and, 568
  thyroid hormones in, 899
  TRH stimulation and DST in, 412
  ulinastatin in, 800
Afternoon
  depressive psychomotor disturbance and, 941
Age
  anorexia nervosa and, 761
  CT ventricular abnormality related to cycloid psychosis and, 1255
  dementia and elevated TSH, 714
  depressive psychomotor disturbance and, 941
  dopamine-related genes and, 1032
  euthyroid sick syndrome among psychiatric inpatients and, 1288
  hippocampal volume in combat-related PTSD and, 1091
  inositol monophosphatase activity and, 656
  MRI in schizophrenia and, 585
  obsessive-compulsive disrder and, 1164
  seasonal variability in 3H-imipramine blood platelet binding and, 981
  serum lipid concentrations in major depressive disorder and, 1128
Aggression
  CFS testosterone and 5-HIAA in, 1067
  prolactin and, 157
  serotonin and, 157
Agoraphobia
  panic disorder and, 913
Akathisia
  B_2-receptor density and, 203
  FK506 and, 407
  nefazodone and, 798
Alanine
  seasonal affective disorder and, 1267
Albumin
  serum concentrations, major depressive disorder and, 1128
Alcohol consumption
  auditory and visual event related potentials and, 284
  hippocampal volume in combat-related PTSD and, 1091
  ondansetron alters human alcohol intoxication, 514
Alcoholism
  in African Americans, dopamine D2 receptor gene polymorphisms and, 144

© 1996 Society of Biological Psychiatry

0006-3223/96/$15.00
PII S006-3223(96)00482-7

D2 dopamine receptor gene *Taq*I A1 and B1 restriction fragment length polymorphisms and, 776
DHEA response to CRH in alcoholism, 1305
inositol 1,4,5-triphosphate binding in platelets and, 886
memory in detoxified alcoholics, 43
schizophrenia onset and, 1155
Alleles
APOE ϵ4 and, 1008
apolipoprotein E4, 811
Allergic cross-reactivity
clozapine-chlorpromazine, 1186-corr
Alpha asymmetry
EEG, female suicide attempters and, 706
Alprazolam
premedication, 35% carbon dioxide vulnerability in panic disorder and, 913
Alzheimer's disease
APOE ϵ4 and, 1008
circadian rest-activity rhythm disturbances and, 259
Down's syndrome and, 811
gamma-aminobutyric acid and, 933
HPA axis and, 61
REM sleep behavior disorder and, 422
Amino acids
excitatory, schizophrenia and, 1298
5-HT_{2A} receptor, seasonal affective disorder and, 1267
obsessive-compulsive disorder and, 398
d-Amphetamine
challenge, behavioral sensitization and, 872
clozapine in schizophrenia and, 834
D2 dopamine receptor gene *Taq*I A1 and B1 restriction fragment length polymorphisms and, 776
Amplitude frequency characteristics
transfer properties in depression and, 736
Amplitude reduction
single trial analysis of event-related potentials and, 844
Analysis of variance (ANOVA)
abnormal recognition of facial expression and, 697
functional brain imaging and, 1106
Angiotensin-converting enzyme (ACE)
chronic pain disorder and, 994
Anhedonia
schizotypal personality disorder and, 853
Anorexia nervosa
positron emission tomography and, 761
Anticipatory saccades
obsessive-compulsive disorder and, 1164
Anticonvulsants
cocaine-induced panic and, 938
Antidepressants
bipolar disorder and, 935
lateralization and, 1282
Antigens
cytotoxic, depression and, 1273
Antipsychotic drugs
IP_3-dependent Ca^{2+} release and, 497
manganese-superoxide dismutase and, 230
Anxiety
acute tryptophan depletion and, 648
cholecystokinin-tetrapeptide and, 302
cocaine-induced panic and, 938
FK506 and, 407
high-energy phosphate metabolism in frontal lobes in panic disorder and, 785
homovanillic acid and, 247
inositol and, 426
naloxone and, 154
schizophrenia and, 597
Anxiolytics
panic disorder and, 913
Apolipoproteins
"elderly" Down's syndrome population and, 811
late life depresssion and, 1008
geriatric depression and, 69
serum concentrations, major depressive disorder and, 1128
Apomorphine (APO)
latent inhibition paradigm and, 1083
Appetite
atypical depression and, 691
Arginine vasopressin
chronic pain disorder and, 994
Arithmetic transformation
functional brain imaging and, 1106
Assaults
and CSF 5-HIAA and testosterone, 1067
Association studies
dopamine D2-like receptors in schizophrenia and, 1209
Astrocytes
carbamazepine and inositolphosphate signalling in, 563
Asymmetry
P3 amplitude, schizotypal personality disorder and, 165
Atmospheric presssure
CSF transfer metabolites and, 682-corr, 683-corr (response)
Attentional deficits
acute ethanol effect on ERPs and, 284
haloperidol and, 1135
latent inhibition paradigm and, 1083
spatial working memory deficits in schizophrenia and, 930
Attention-deficit hyperactivity disorder (ADHD)
blink rate and, 1222
continuous-processing event-related potentials and, 964
corpus callosum and, 1060
event-related potentials and, 522
lateral ventricles and, 1060
magnetic resonance imaging and, 1060
quantitative EEG and, 951
smooth pursuit eye movements in, 1144
zinc deficiency and, 1308
"Attentive" conditions
schizophrenia and, 597
Atypical depression
neurovegetative symptoms in, 691
Auditory-evoked potentials (AEPs)
acute alcohol effect and, 284

schizophrenia and, 19, 181
sensory gating in schizophrenia and, 1230
thalamic, ECT and, 807
transfer properties in depression and, 736
Auditory paradigm
haloperidol and, 1135
Autism
infantile, X chromosome and, 457
Autoantibodies
organ-nonspecific, schizophrenia and, 825
Autoimmune process
organic psychosis and, 292
Autopsy
Alzheimer's disease and, 422
Autoreceptor desensitization
REM sleep deprivation and, 1000
Autoregulation
cerebral, postural syncope and, 923

Backward masking
schizophrenia and, 295
Basal ganglia
insertion/deletion polymorphism in angiotensin converting enzyme gene and, 1122
proton MRS of, schizophrenia and, 14
Base pair sequences
dopamine D2-like receptors in schizophrenia and, 1209
Beck Depression Inventory
and spontaneous orgasm with combined use of bupropion and sertraline, 1184-corr
Behavioral effects
acute tryptophan depletion and, 648
d-amphetamine challenge and, 872
naloxone inn obsessive-compulsive disorder and, 154
seasonal affective disorder and, 1267
Benzodiazepine receptors
peripheral type, major depression and, 221
Beri beri
second-trimester, schizophrenia and, 1-ed
B_2-receptor density
akathisia and, 203
Biological clocks
cortisol release in major depression and PTSD, 79
Biological markers
Alzheimer's disease and, 933
inositol 1,4,5-triphosphate binding in alcoholism and, 886
tridimensional personality questionnaire measures and, 271
Bipolar disorder
carbamazepine in, 935
cerebellum and, 726
choline in, 382
dentatorubrothalamic tract and, 726
dim-light melatonin onset and, 731
α1-microglobulin in, 800
National Institute of Mental Health Workshop report on, 215
protein kinase C in, 568
self-report mania rating scales and, 279
substantia nigra and, 726
ulinastatin in, 800
Birth complications
CT ventricular abnormality related to cycloid psychosis and, 1255
low weight, neurocognitive status and, 389
schizophrenic, 817, 1200
Blink rate
d-amphetamine challenge and, 872
attention-deficit hyperactivity disorder and, 1222
childhood-onset schizophrenia and, 1222
schizophrenia and, 597
Blood-brain barrier
fluoxetine and, 361
Blood pressure
cranial blood flow after cocaine hydrochloride and, 609
stress response in remitted panic disorder and, 353
Body height
dopamine-related genes and, 1032
increased head circumference in schizophrenia and, 1173
Body weight
atypical depression and, 691
dopamine-related genes and, 1032
gain, anorexia nervosa and, 761
serum lipid concentrations in major depressive disorder and, 1128
Borderline personality disorder
bulimia nervosa and, 173
platelet monoamine measures and, 173
recurrent suicidal behavior and, 173
serotonergic resonsivity in, 508
TRH stimulation and DST in, 412
Borna disease virus rats
prefrontal dysfunction in, 629
Brain
glucose hypometabolism, anorexia nervosa and, 761
synaptosomes, glucocorticoids and serotonin transporter, 576
whole, functional brain imaging and, 1106
Brainstem
REM sleep behavior disorder, 422
transient emotion and, 859
Brief Psychiatric Rating Scale
schizophrenia and, 755
Bright-light treatment
thyroid hormones in nonseasonal affective disorders and, 899
Bromocriptine
depression and, 151
Brown-Goodwin Aggression—Revised
prolactin response to d-fenfluramine and, 157
Buprenorphine
and P300 amplitude in opiate and cocaine users, 617
Bupropion
sertraline with, spontaneous orgasm and, 1184-corr
Buss-Durkee Hostility Inventory-Assault Scale
prolactin response to d-fenfluramine and, 157

Butaclamol
D2-like dopamine receptors and, 881

Ca^{2+}, 1267
antipsychotic drugs block release of, 497
inositolphosphate signalling with, carbamazepine and, 563
CA3 neural network
hippocampal, sensory gating and, 1230
Cacosmia
B-endorphin in, 134
sleep disturbance in, 123
Caffeine
ECT augmented with, hippocampal neurons and, 642
schizophrenia and, 1218
Calcium
major depression and, 428
Callithrix jacchus jacchus biobehavioral consequences of social stress and, 317
Carbamazepine
astrocytes and, 563
bipolar disorder and, 935
Carbon dioxide (CO_2)
challenge, panic disorder and, 913
Cardiovasculare responses
acute tryptophan depletion and, 648
stress response in remitted panic disorder and, 353
Cataplexy
narcolepsy and, 208
Catatonia
neuroleptic malignant syndrome and, 431-corr, 432-corr (response)
Catecholamines
homovanillic acid and, 247
Caucasians
water intoxication in, 28
CD8
serum soluble, depression and, 1273
Central regions
cranial blood flow after cocaine hydrochloride and, 609
Centre d'Etude du Polymorphism Humain population controls
seasonal affective disorder and, 1267
Cerebellum
bipolar disorder and, 726
compulsion and, 726
dystonia and, 726
Cerebral blood flow
global, functional brain imaging and, 1106
regional, attention-deficit hyperactivity disorder and, 951
regional, autoregulation of and postural syncope, 923
regional, cocaine hydrochloride and, 609
regional, haloperidol and, 604
regional, transient emotion and, 859
Cerebral cortex
attention-deficit hyperactivity disorder and, 951
PCP and, 1246
Cerebral metabolism
anorexia nervosa and, 761
TSH elevation and, 714
Cerebrospinal fluid (CSF)
angiotensin-converting enzyme, chronic pain disorder and, 994
fluoxetine and, 361
gamma-aminobutyric acid, Alzheimer's disease and, 933
5-HIAA, aggressive behavior and, 1067
monoamine metabolites, dopamine-related genes and, 1032
neurotransmitters, increased CCK-4 in simvastatin administration and, 302
rearing experience and biogenic amine activity, 338
subarachnoidal, hippocampal volume in combat-related PTSD and, 1091
testosterone, aggressive behavior and, 1067
transmitter metabolites, atmospheric pressure and, 682-corr, 683-corr (response)
Cericlamine
REM sleep deprivation and, 1000
Chase sequences
prolonged, and CSF 5-HIAA and testosterone, 1067
Chemical odor intolerance
sleep disturbance and, 123
Children
attention-deficit hyperactivity disorder in, 522, 553, 951, 964, 1060, 1144
depressed, stressful life events influence nocturnal growth hormone in, 1176
low birth weight and neurocognitive status, 389
schizophrenic, smooth pursuit eye movements in, 1144
Tourette's syndrome in, 1044
m-Chlorophenylpiperazine (m-CPP)
borderline personality and, 508
headache response to in obsessive-compulsive disorder, 544
Chlorpromazine
clozapine allergic cross-reactivity with, in psychotic patient with asymptomatic AIDS, 1186-corr
Choking feeling
clozapine and, 1132
Cholecystokinin (CCK)
inositol-induced anxiety and, 426
Cholecystokinin-B (CCK-B) receptor antagonist
receptor antagonist, lactate-induced panic and, 550, 804
Cholecystokinin tetrapeptide (CCK-4)
acute tryptophan depletion and, 648
Cholesterol
lowering, increased CCK-4 in simvastatin administration and, 302
lowering, risks of, 686-corr
serum, treatment-resistant schizophrenia and, 542
serum total, major depressive disrder and, 1128 sleep panic disorder and, 1064
Choline
proton MRS of basal ganglia in schizophrenia and, 14
rapid cycling bipolar diosrder and, 382
Cholinergic system
schizophrenia and, 660
Chronic fatigue syndrome
cognitive deficits in, 535

Chronic pain disorder
CSF angiotensin-converting enzyme and, 994
plasma vasopressin and, 994
Chronobiological analysis
cortisol release in major depression and PTSD, 79
Chronotherapy
delayed sleep phase syndrome and, 794
CI-988
lactate induced panic and, 550
Cingulate gyrus
schizophrenia and, 1191
transient emotion and, 859
Circadian rhythms
Alzheimer's disease and, 259
cortisol release in major depression and PTSD, 79
delayed sleep phase syndrome and, 794
dim-light melatonin onset in rapid cycling bipolar disorder and, 731
Circulation
cranial blood flow after cocaine hydrochloride and, 609
Citalopram
REM sleep deprivation and, 1000
Clinical Global Impression Scale
fluoxetine vs. phenelzine in atypical depression and, 1017
Clomipramine
lithium with, 1181
obsessive-compulsive disorder and, 908
plasma serotonin and, 465
Clonazepam
panic disorder and, 913
Clozapine
chlorpromazine allergic cross-reactivity with, in psychotic patient with asymptomatic AIDS, 1186-corr
IP_3-dependent Ca^{2+} release and, 497
psychotic depression and, 253
saliva flow rate and, 1132
schizophrenia and, 181, 542, 834, 1056, 1222
Cocaine
crack, quantitative EEG and, 986
D2 dopamine receptor gene *Taq*I A1 and B1 restriction fragment length polymorphisms and, 776
hydrochloride, cranial blood flow changes and, 609
P300 amplitude and, 617
panic disorder amd, 938
Cognitive function
APOE ϵ4 and, 1008
chronic fatigue syndrome and, 535
depression and, 1282
memory in detoxified alcoholics and, 43
and P300 amplitude in opiate and cocaine users, 617
schizophrenia and, 434-corr
subclinical hypothyroidism and, 714
Collagen
platelet dense granule secretion and, 892
Combat veterans
hippocampal volume in PTSD and, 1091
with and without PTSD, prolactin response to low-dose dexamethasone challenge in, 1100
Community-based study
dementia and elevated TSH, 714
Comorbidity
platelet dense granule secretion and, 892
substance abuse and schizophrenia, 1155
Competitive aggression
and CSF 5-HIAA and testosterone, 1067
Completers
study, difference of from study dropouts, 668
Compulsion
cerebellum and, 726
dentatorubrothalamic tract and, 726
substantia nigra and, 726
Computed tomography (CT)
functional brain imaging and, 1106
obstetric complications in schizophrenia and, 1200
ventricular abnormality, cycloid psychosis and, 1255
Computer modeling
CA3 neural network of hippocampus and, 1230
Conditioned emotional response
clozapine in schizophrenia and, 834
Conduct disorder
platelet dense granule secretion and, 892
Confirmatory factor analysis
schizophrenia and, 755
Contigent negative variation
suicidal behavior in depression and, 116
Continuous-processing-related event-related potentials
attention-deficit hyperactivity disorder and, 964
Control
impaired impulse, and CSF 5-HIAA and testosterone, 1067
Convulsions
caffeine-augmented ECT and, 642
CORE scale
depressive psychomotor disturbance and, 941
Corpus callosum
attention-deficit hyperactivity disorder and, 1060
Cortical perfusion
regional cerebral blood flow after haloperidol and, 604
Cortical sulci
schizophrenia and, 1200
Corticotropin
HPA axis in Alzheimer's disease and, 61
Corticotropin-releasing hormone (CRH)
adrenal gland volume in major depression and, 89
DHEA response top in alcoholism, 1305
Cortisol
acute tryptophan depletion and, 648
adolescent depression and, 474
adrenal gland volume in major depression and, 89
biobehavioral consequences of social stress and, 317
delayed sleep phase syndrome and, 794
depression and, 1273
depression in chronic vasculopathic patients and, 637
depressive psychomotor disturbance and, 941
dexamethasone challenge in combat veterans with and

without PTSD and, 1100
fenfluramine in Parkinson's disease and, 769
HPA axis in Alzheimer's disease and, 61
major depression and, 79
PTSD and, 79
schizophrenia and, 660, 927
stress response in remitted panic disorder and, 353
Crack cocaine
quantitative EEG and, 986
Critical stimulus duration
schizotypal personality disorder and, 853
Cross-cultural event-related potential stidy
schizophrenia and, 189
Cross-reactivity
allergic, clozapine-chlorpromazine, 1186-corr
C-terminal receptor tail
seasonal affective disorder and, 1267
Cycloid psychosis
computed tomography ventricular abnormality and, 1255
D-Cycloserine
drug-free schizophrenics and, 1298
Cytochrome P-450 2D6 polymorphism
neuroleptic malignant syndrome and, 72
Cytokines
acute schizophrenic psychosis and, 1294
delayed sleep phase syndrome and, 794
obsessive-compulsive disorder and, 908

Dairy products
environmental chemical odor intolerance and, 123
Daytime sleepiness
excessive, narcolepsy and, 208
Deglutition
clozapine and, 1132
Dehydroepiandrosterone (DHEA)
corticotropin-releasing hormone stimulation in alcoholism and, 1305
Delayed sleep phase syndrome
light and chronotherapy in, 794
Dementia
elevated TSH and, 714
Denmark
schizophrenia and, 817
Dentatorubral-pallidoluysian atrophy
schizophrenia and, 228
Dentatorubrothalamic tract
bipolar disorder and, 726
compulsion and, 726
dystonia and, 726
Depression
abnormal recognition of facial expression in, 697
in adolescents, 474
adrenal gland volume in, 89
bromocriptine in, 151
calcium in, 428
carbamazepine in, 935
CD8 in, 1273
cerebral hemispheres in, 1282
choline in, 382
in chronic vasculopathic patients, 637
clozapine in, 253
cortisol in, 79
ECS down-regulation of peripheral-type benzodiazepine receptors in, 221
ECT effect on thalamic auditory potential and, 807
EEG alpha asymmetry in female suicide attempters, 706
fenfluramine in Parkinson's disease and, 769
fluoxetine vs. phenelzine in, 1017
functional brain imaging and, 1106
glucocorticoids and, 1273
glucocorticoids and serotonin transporter, 576
imipramine with lithium for, 1181
information processing in, 98
lateralized neuropsychological functioning in, 1282
magnesium in, 428
α1-microglobulin in, 800
nefazodone in, 798
neurovegetastive symptoms in, 691
in pre-and postmenopausal women, 403
protein kinase C in, 568
serum lipid concentrations in, 1128
single trial analysis of event-related potentials in, 844
social isolation in, 918
stressful life events influence nocturnal growth hormone secretion in children, 1176
study dropouts/completers and, 668
suicidal behavior in, 116
suppressor/cytotoxic antigens in, 1273
thyroid hormones in, 428, 899
transcranial magnetic stimulation in, 148
transfer properties in sleep and, 736
tryptophan depletion in obsessive-compulsive disorder and, 398
tyrosine hydroxylase RFLP in, 305
ulinastatin in, 800
Desipramine
flupoxetine and, 361
lithium with, 1181
Detoxification
memory in detoxified alcoholics, 43
and P300 amplitude in opiate and cocaine users, 617
Development
fluoxetine and, 361
Dexamethasone (DEX)
glucocorticoids and serotonin transporter, 576
Dexamethasone suppression test (DST)
borderline personality disorder and, 412
depression and, 1273
depression in chronic vasculopathic patients and, 637
melancholia and, 941
nonsuppression, schizophrenia and, 660
nonsuppression, short rapid eye movement latency in schizophrenia and, 927
prolactin response to in PTSD, 1100
Diet

schizophrenia and, 1218
Digit span
auditory, event-related potentials in schizophrenia and, 19
Dihydroxyphenylacetic acid
rearing experience and biogenic amine activity, 338
Dimensional analysis
and CSF 5-HIAA and testosterone, 1067
Dim-light melatonin onset (DLMO)
rapid cycling bipolar disorder and, 731
Dim-light treatment
thyroid hormones in nonseasonal affective disorders and, 899
Disease markers
schizophrenia and, 825
Disorganization symptoms
event-related potentials in schizophrenia and, 19
Dizocilpine
schizophrenia and, 744
sensory gating and, 744
DNA analysis
neuroleptic malignant syndrome and, 72
Dopamine
blink rate and, 1222
bromocriptine and, 151
D1 receptor, 1191
D2 receptor, 144, 368, 776, 881, 1209
genes related to, monoamine metabolites and, 1032
prefrontal cortex in Borna disease virus rats and, 629
schizophrenia and, 295, 419, 597
spatial working memory deficits in schizophrenia and, 930
Dopaminergic drugs
latent inhibition paradigm and, 1083
Doppler ultrasonography
laser, cranial blood flow after cocaine hydrochloride and, 609
Dorsal raphe nucleus
REM sleep deprivation and, 1000
Down's syndrome
apolipoprotein E4 allele and, 811
Drooling
clozapine and, 1132
Drug abuse
schizophrenia onset and, 1155
DSM-III-R
atypical depression and, 691
CT ventricular abnormality related to cycloid psychosis and, 1255
dementia and, 714
euthyroid sick syndrome among psychiatric inpatients and, 1288
panic disorder and, 913
Dual energy X-ray absorptiometry
schizophrenia and, 430-corr
Dystonia
cerebellum and, 726
dentatorubrothalamic tract and, 726
substantia nigra and, 726
Early auditory memory function
schizophrenia and, 299
Early experience
biogenic amine activity and, 338
Education level
dementia and elevated TSH, 714
obsessive-compulsive disrder and, 1164
Ego Impairment Index
schizotypal personality disorder and, 853
Elderly
cacosmic, environmental chemical odor intolerance and, 123, 134
dementia and elevated TSH, 714
depression in, *APOE* ϵ4 allele and, 1008
depression in, apolipoprotein E-ϵ4 frequency and, 69
Down's syndrome in, 811
Electroconvulsive shock (ECS)
caffeine-augmented, hippocampal neurons and, 642
down-regulation of platelet peripheral-type benzodiazepine receptors in major depression and, 221
no loss of hippocampal hilar somatostatinergic neurons after, 54
prolactin and TSH responses to in women with major depression, 403
thalamic auditory potential and, 807
TIS gene induction and, 503
Electroencephalogram (EEG)
female adolescent suicide attempters and, 706
schizophrenia and, 452
sleep, cyclic alternating pattern of in panic disorder, 225
sleep, seasonal affective disorder and, 485
sleep, transfer properties in depression and, 736
Electrophysiology
QEEG characteristics of crack cocaine dependence and, 986
transcranial magnetic stimulation and, 148
Emotions
abnormal recognition of facial expression and, 697
Empirical evaluation
schizophrenia and, 755
Encephalitis
organic psychosis and, 292
B-Endorphin
biobehavioral consequences of social stress and, 317
cacosmia and, 134
HPA axis in Alzheimer's disease and, 61
Energy level
d-amphetamine challenge and, 872
Entorhinal cortex
sensory gating in schizophrenia and, 1230
Environmental stressors
chemical odor intolerance and, 123, 134
stress response in remitted panic disorder and, 353
Epidemics
influenza, schizophrenia and, 817
Epinephrine
urinary, during intelligence testing in attention-deficit

hyperactivity disorder boys, 553
Erratum, 78, 1351
Escalated aggression
and CSF 5-HIAA and testosterone, 1067
Estrogen
mood disorders and, 1051
Ethanol
auditory and visual event related potentials and, 284
Ethnicity
increased head circumference in schizophrenia and, 1173
Euphoria
transient emotion and, 859
Euthyroid sick syndrome
psychiatric inpatients and, 1288
Event-related potentials (ERPs)
acute alcohol effect and, 284
attention-deficit hyperactivity disorder and, 522
combat-related PTSD and, 373
continuous-processing-related, ADHD and, 964
information processing in depression and, 98
and P300 amplitude in opiate and cocaine users, 617
schizophrenia and, 19, 189
single trial analysis and, 844
suicidal behavior in depression and, 116
transfer properties in depression and, 736
Exons
dopamine D2-like receptors in schizophrenia and, 1209
Explicit memory
in detoxified alcoholics, 43
Extrapyramidal side effects
regional cerebral blood flow after haloperidol and, 604
Tourette's syndrome and, 1044
Eye tracking
attention-deficit hyperactivity disorder and, 1144
childhood-onset schizophrenia and, 1144, 1222
obsessive-compulsive disrder and, 1164

Facial expression
abnormal recognition of, 697
schizophrenia and, 556
Factorial structure
of clinical symptoms, schizophrenia and, 755
Family history
schizophrenia and, 825
Famine
schizophrenia and, 1-ed
Fast segmantation
of neural processing, schizophrenia and, 1301
Fenfluramine
Parkinson's disease and, 769
prolactin and, 157
Fetal malnutrition
schizophrenia and, 1-ed
Fimbria-fornix lesions
sensory gating in schizophrenia and, 1230
First trimester
malnutrition, schizophrenia and, 1-ed
FK506
side effects and, 407
(18-F)-Fluorodeoxyglucose
anorexia nervosa and, 761
schizophrenia and, 443
Fluoxetine
CSF and, 361
phenelzine vs. atypical depression and, 1017
study dropouts/completers and, 668
cis-Flupenthixol (FLU)
latent inhibition paradigm and, 1083
Fluspirilene
IP_3-dependent Ca^{2+} release and, 497
Fluvoxamine
clozapine-resistant schizophrenia and, 671
melatonin and, 75
Food
environmental chemical odor intolerance and, 123, 134
Foot shock
clozapine in schizophrenia and, 834
Forehead skin flow
cranial blood flow after cocaine hydrochloride and, 609
40-Hz activity
schizophrenia and, 1301
Free radicals
manganese-superoxide dismutase and, 230
Frontal cortex
anorexia nervosa and, 761
schizophrenia and, 1191
spatial working memory deficits in schizophrenia and, 930
Frontal lobes
cranial blood flow after cocaine hydrochloride and, 609
high-energy phosphate metabolism in panic disorder and, 785
MRI in schizophrenia and, 585
Frontal/striatal system
attention-deficit hyperactivity disorder and, 951
schizophrenia and, 1021
Functional brain imaging
four normalizing methods on data analyisis and, 1106

Gamma-aminobutyric acid (GABA)
Alzheimer's disease and, 933
Gender
acute tryptophan depletion and, 648
aggression and, 157
anorexia nervosa and, 761
CCK-4 in simvastatin administration and, 302
CT ventricular abnormality related to cycloid psychosis and, 1255
dementia and elevated TSH, 714
dopamine-related genes and, 1032
EEG alpha asymmetry in female suicide attempters, 706
euthyroid sick syndrome among psychiatric inpatients and, 1288
gray matter deficits in young onset schizophrenia and, 4
HPA axis in Alzheimer's disease and, 61
increased head circumference in schizophrenia and, 1173
MRI in schizophrenia and, 585

neuropsychology and olfaction in schizophrenia and, 1021
obsessive-compulsive disorder and, 1164
schizophrenia and, 755, 1200
seasonal variability in 3H-imipramine blood platelet binding and, 981
serum lipid concentrations in major depressive disorder and, 1128
sleep EEG in seasonal affective disorder and, 485
transient self-induced sadness or happiness and, 859
Genes
angiotensin converting enzyme, 1122
dentatorubral, 228
dopamine receptor, 144, 368, 419, 776, 1032, 1209
inositol monophosphatase activity and, 656
pallidoluysian, 228
small effect, behavior and, 313-ed
TIS, 503
tyrosine hydroxylase, 1032
Genotype
monoamine metabolites and, 1032
neuroleptic malignant syndrome and, 72
Geriatric depression
APOE ϵ4 allele and, 1008
apolipoprotein E-ϵ4 frequency and, 69
Global mean perfusion
regional cerebral blood flow after haloperidol and, 604
Glucocorticoids
depression and, 1273
serotonin transporter and, 576
Glucose
hypometabolization, anorexia nervosa and, 761
Glutamate
schizophrenia and, 1298
Glycine
schizophrenia and, 684-corr, 685-corr (response), 1298
Gradient relationship
low birth weight and neurocognitive status, 389
Granulocytosis
schizophrenia and, 825
Gray matter
deficits, young onset schizophrenia in, 4
MRI in schizophrenia and, 585
Growth hormone (GH)
delayed sleep phase syndrome and, 794
depression in chronic vasculopathic patients and, 637
nocturnal secretion in depressed children, 1176

Habituation
environmental chemical odor intolerance and, 134
Hallucinations
musical, tricyclic-induced, 309-corr, 310-corr (response)
schizophrenia and, 597
Haloperidol
cerebral cortex blood flow and, 604
D2-like dopamine receptors and, 881
IP_3-dependent Ca^{2+} release and, 497
prolactin monitoring of, Tourette's syndrome and, 1044
schizophrenia and, 1135
Hamilton Depression Rating Scale
atypical depression and, 691
fluoxetine vs. phenelzine in atypical depression and, 1017
Handedness
tardive dyskinesia and, 35
Happiness
self-induced, gender and, 859
Headache
post-lumbar-puncture, menstrual cycle and, 310-corr
response, m-CPP in obsessive-compulsive disorder and, 544
Head circumference
increased, schizophrenia, 1173
Helplessness
suicidal behavior in depression and, 116
Hemispheric asymmetry
abnormal recognition of facial expression and, 697
EEG alpha asymmetry in female suicide attempters, 706
schizophrenia and, 299
Hemispheric functioning
depression and, 1282
Heroin
P300 amplitude and, 617
Heterocyclic-resistant depression
bromocriptine in, 151
Heterozygosity
insertion/deletion polymorphism in angiotensin converting enzyme gene and, 1122
High-density lipoprotein (HDL)
cholesterol serum concentrations, major depressive disorder and, 1128
Hippocampus
astrocyte cultures, carbamazepine and, 563
CA3 neural network, sensory gating and, 1230
hilar somatostatinergic neurons, ECT and, 54
neurons, caffeine-augmented ECT and, 642
volume, in combat-related PTSD, 1091
Histidine
seasonal affective disorder and, 1267
Histochemical analysis
Alzheimer's disease and, 422
Homovanillic acid (HVA)
aggression and, 1067
anxiety and, 247
dopamine-related genes and, 1032
rearing experience and biogenic amine activity, 338
schizophrenia and, 1218
Homozygosity
tyrosine hydroxylase RFLP, 305
Hopelessness
suicidal behavior in depression and, 116
5-Hydroxyindoleacetic acid (5-HIAA)
aggressive behavior and, 1067
dopamine-related genes and, 1032
rearing experience and biogenic amine activity, 338
5-Hydroxytryptamine$_{2A}$ (5-HT_{2A})
receptor gene coding region, seasonal affective disorder and, 1267

Hygiene deficits
schizophrenia and, 1021
Hyperactivity
prefrontal cortex in Borna disease virus rats and, 629
Hyperarousal
attention-deficit hyperactivity disorder and, 951
Hypoarousal
attention-deficit hyperactivity disorder and, 951
Hyponatremia
polydipsia and, 28
Hypothalamic-pituitary-adrenal (HPA) axis
Alzheimer's disease and, 61
biobehavioral consequences of social stress and, 317
cortisol release in major depression and PTSD, 79
depression and, 1273
schizophrenia and-corr, 560, 561-corr (response)
Hypothalamic-pituitary-ovarian axis
mood and, 1051
Hypothyroidism
subclinical, dementia and, 714

ICD-10
CT ventricular abnormality related to cycloid psychosis and, 1255
Imipramine
blood platelet binding, seasonal variability in, 981
glucocorticoids and serotonin transporter, 576
lithium with, major depression and, 1181
Immunoblotting analysis
inositol 1,4,5-triphosphate binding in alcoholism and, 886
Impulsivity
in bulimia nervosa and suicidality, 173
and CSF 5-HIAA and testosterone, 1067
Incidence cases
schizophrenia and, 817
Infantile autism
X chromosome and, 457
Inferior frontal cortex
anorexia nervosa and, 761
Inflammatory process
schizophrenia and, 825
Influenza epidemics
in utero exposure to, schizophrenia and, 817
Information processing deficits
depression and, 98
schizotypal personality disorder and, 853
Innervation
dopaminergic, medial prefrontal cortex and, 1083
Inositol
anxiety and, 426
Inositol monophosphatase
brain activity of, 656
Inositolphosphate
astrocytes and, 563
Inositol 1,4,5-triphosphate (IP_3)
antipsychotic drugs and, 497
platelets from alcoholics and, 886
In situ hybridization
hippocampal hilar somatostatinergic neurons after ECT and, 54
Insomnia
environmental chemical odor intolerance and, 123
Intelligence testing
attention-deficit hyperactivity disorder boys and, 553
Interferon γ (IFN-γ)
schizophrenia and, 1294
Interindividual variability
insertion/deletion polymorphism in angiotensin converting enzyme gene and, 1122
Interleukins
obsessive-compulsive disorder and, 908
schizophrenia and, 1294
Intermittent stimulant exposure
behavioral sensitization and, 872
Internal State Scale
self-reporting of mania and, 279
Intoxication
alcohol, ondansetron alters, 514
cranial blood flow after cocaine hydrochloride and, 609
water, polydipsia and, 28
Intracranial cavity
hippocampal volume in combat-related PTSD and, 1091
Intrathecal compartment
leukocyte trafficking in, fluoxetine and, 361
In utero exposure
to influenza epidemic, schizophrenia, 817
IRAOS structured interview
substance abuse in schizophrenia onset and, 1155
Irrelevant stimuli
latent inhibition paradigm and, 1083
Isolation models
neuropsychiatric disorders and, 918
Isozymes
brain protein kinase C, 568

Japanese population
schizophrenia in, insertion/deletion polymorphism in angiotensin converting enzyme gene and, 1122

Kindling
cocaine-induced panic and, 938

L-365,260
lactate-induced panic attacks in panic disorder and, 804
Lactate
panic attacks induced by, 550, 804
Latency
REM, schizophrenia and, 660, 927
single trial analysis of event-related potentials and, 844
Latent inhibition model
haloperidol and, 1135
local application of dopaminergic drugs into medial prefrontal cortex and, 1083
of schizophrenia, 834
Lateralization
depression and, 1282

Lateral ventricles
attention-deficit hyperactivity disorder and, 1060
Leaps
impulsive, and CSF 5-HIAA and testosterone, 1067
Learning
chronic fatigue syndrome and, 535
Left hemifield of vision
abnormal recognition of facial expression and, 697
Leonhard Classification
CT ventricular abnormality related to cycloid psychosis and, 1255
Leukocytes
schizophrenia and, 825
trafficking, fluoxetine and, 361
Licking behavior
clozapine in schizophrenia and, 834
Life Skills Profile
schizophrenia and, 1021
Lifetime alcohol consumption
hippocampal volume in combat-related PTSD and, 1091
Light-dark cycle
Alzheimer's disease and, 259
Light treatment
delayed sleep phase syndrome and, 794
sleep EEG in seasonal affective disorder and, 485
Limbic system
PCP and, 1246
transient emotion and, 859
Linear system theory
transfer properties in depression and, 736
Linkage analysis
dopamine D2-like receptors in schizophrenia and, 1209
Lipids
serum concentrations, major depressive disorder and, 1128
Lithium
brain *myo*-inositol and, 235
carbamazepine and, 563
choline in rapid-cycling bipolar disorder and, 382
imipramine with, major depression and, 1181
Lorazepam
schizophrenia and, 1218
Lymphocytes
D2-like dopamine receptors and, 881
depression and, 1273
fluoxetine and, 361
schizophrenia and, 825

Macrocephaly
head circumference in schizophrenia and, 1173
Magnesium
major depression and, 428
Magnetic resonance imaging (MRI)
adrenal gland volume in major depression and, 89
attention-deficit hyperactivity disorder and, 951, 1060
gray matter deficits in young onset schizophrenia and, 4
hippocampal volume in PTSD and, 1091
schizophrenia and, 585
Magnetic resonance spectroscopy (MRS)
choline in rapid-cycling bipolar disorder and, 382
high-energy phosphate metabolism in frontal lobes in panic disorder and, 785
lithium and, 235
proton, of basal ganglia in schizophrenia, 14
Magnetoencephalography
schizophrenia and, 299
Major depressive disorder
abnormal recognition of facial expression in, 697
in adolescents, 474
adrenal gland volume in, 89
APOE ϵ4 and, 1008
calcium in, 428
CD8 in, 1273
cortisol in, 79
ECS down-regulation of peripheral-type benzodiazepine receptors in, 221
fenfluramine in Parkinson's disease and, 769
functional brain imaging and, 1106
glucocorticoids and, 1273
imipramine with lithium for, 1181
magnesium in, 428
α1-microglobulin in, 800
in pre-and postmenopausal women, 403
serum lipid concentrations in, 1128
suppressor/cytotoxic antigens in, 1273
thyroid hormones in, 428
tridimensional personality questionnaire measures and, 271
ulinastatin in, 800
Malnutrition
schizophrenia and, 1-ed
Manganese-superoxide dismutase
postmortem brain of neuroleptic-treated psychotics and, 230
Mania
carbamazepine and, 935
self-report rating scales and, 279
Marmoset
common, biobehavioral consequences of social stress and, 317
Masking stimulus
abnormal recognition of facial expression and, 697
Maternal exposure
to influenza in pregnancy, schizophrenia and, 817
Medial septal nucleus
sensory gating in schizophrenia and, 1230
Medication status
backward masking in schizophrenia and, 295
Melancholia
depressive psychomotor disturbance and, 941
Melatonin
fluvoxamine and, 75
rapid cycling bipolar disorder and, 731
slow-wave sleep deprivation and, 664
Memory
chronic fatigue syndrome and, 535
detoxified alcoholics and, 43
schizophrenia and, 299, 443, 1021

Menopause
major depression and, 403
Menstrual cycle
post-lumbar-puncture headache and, 310-corr
Mental effort
information processing in depression and, 98
Mesocortex
prefrontal cortex in Borna disease virus rats and, 629
Messenger RNA (mRNA)
D2-like dopamine receptors and, 881
Metabolism
cerebral, anorexia nervosa and, 761
cerebral, thyroid state and, 714
dopamine, backward masking in schizophrenia and, 295
high-energy phosphate, panic disorder amd, 785
3-Methoxy-4-hydroxyphenylglycol (MHPG)
dopamine-related genes and, 1032
rearing experience and biogenic amine activity, 338
Microcephaly
head circumference in schizophrenia and, 1173
α1-Microglobulin
urinary ulinastatin levels and, 800
Microsomes
brain, IP_3-dependent Ca^{2+} release and, 497
Microstructure
sleep, panic disorder and, 225
Microtus ochrogaster
social isolation and, 918
Midday light treatment
sleep EEG in seasonal affective disorder and, 485
Midgestation
schizophrenia and, 817
Mismatch negativity
acute ethanol effect on ERPs and, 284
attention-deficit hyperactivity disorder and, 522
Monoamine metabolites
CSF, dopamine-related genes and, 1032
Monoamine oxidase
smoking and, 433-corr
Monoaminergic responses
stress response in remitted panic disorder and, 353
Monocytosis
schizophrenia and, 825
Mononuclear blood cells
B_2-receptor density and, 203
Mood
d-amphetamine challenge and, 872
cranial blood flow after cocaine hydrochloride and, 609
dim-light melatonin onset in rapid cycling bipolar disorder and, 731
tryptophan depletion in obsessive-compulsive disorder and, 398
Mood disorders
euthyroid sick syndrome among psychiatric inpatients and, 1288
hypothalamic-pituitary-ovarian axis and, 1051
α1-microglobulin in, 800
transient emotion and, 859
ulinastatin in, 800
Morphology
brain, age-related changes in schizophreni and, 1200
Multiple target velocity task
obsessive-compulsive disrder and, 1164
Myo-inositol
brain, lithium and, 235

N1 amplitude
combat-related PTSD and, 373
N2 amplitude
combat-related PTSD and, 373
N40 amplitude
sensory gating in schizophrenia and, 1230
N200 amplitude
event-related potentials in schizophrenia and, 19
N-acetyl aspartate (NAA)
proton MRS of basal ganglia in schizophrenia and, 14
Naloxone
obsessive-compulsive disorder and, 154
Narcolepsy
diagnostic features in, 208
National Institute of Mental Health Workshop report
on bipolar disorder, 215
Nefazodone
akathisia and, 798
Negative symptoms
schizophrenia and, 930, 1021, 1209, 1298
Nested PCR
D2-like dopamine receptors and, 881
Neural networks
hippocampal, sensory gating and, 1230
overarousal and, 19
Neural processing
schizophrenia and, 1301
Neurobiology
prolactin response to DST challenge in combat veterans and, 1100
Neurocognitive impairments
low birth weight and, 389
schizophrenia and, 597
Neurodevelopment
cycloid psychosis and, 1255
Neuroendocrine responses
nondepressed vasculopathic patients and, 637
stress response in remitted panic disorder and, 353
Neuroleptic malignant syndrome
catatonia and, 431-corr, 432-corr (response)
cytochrome P-450 2D6 polymorphism and, 72
Neuroleptics
akathisia and, 203
atypical, schizophrenia and, 834, 1056
D2-like dopamine receptors and, 881
frontal cortical dopamine D1 receptors and, 1191
manganese-superoxide dismutase and, 230
regional cerebral blood flow after haloperidol and, 604
saliva flow rate and, 1132

schizophrenia and, 597, 755
tardive dyskinesia and, 35
Tourette's syndrome and, 1044
Neurological soft signs
risperidone response in schizophrenia and, 1056
Neurometrics
QEEG characteristics of crack cocaine dependence and, 986
Neurons
central serotoninergic, REM sleep deprivation and, 1000
hippocampal, caffeine-augmented ECT and, 642
hippocampal hilar somatostatinergic, ECT and, 54
proton MRS of basal ganglia in schizophrenia and, 14
Neuropeptide Y (NPY)
PCP,and, 1246
Neurophysiologic deficits
schizotypal personality disorder and, 853
Neuropsychological deficits
depression and, 1282
schizophrenia and, 295, 1021
Neurotransmitters
anorexia nervosa and, 761
CSF, increased CCK-4 in simvastatin administration and, 302
Neurotropic virus
prefrontal cortex in Borna virus disease rats and, 629
Neurovegetative symptoms
stability of, 691
Neutral states
transient emotion and, 859
Newcastle scale
depressive psychomotor disturbance and, 941
News and Notes, 233, 436, 562, 688, 814, 1311
Nicotine
schizophrenia and, 1218
sensory gating in schizophrenia and, 1230
N-methyl-D-aspartate (NMDA) receptor
PCP and, 1246
schizophrenia and, 1298
Nocturnal secretion
growth hormone, in depressed children, 1176
Nonhuman primates
and CSF 5-HIAA and testosterone, 1067
Nonreinforced preexposure
to stimulus, latent inhibition and, 1083
Non-REM sleep
transfer properties in depression and, 736
Nonseasonal affective disorders
thyroid hormones and, 899
Norepinephrine
rearing experience and biogenic amine activity, 338
Normalization method
functional brain imaging and, 1106
Northern blot analysis
D2-like dopamine receptors and, 881
Nortryptiline
lithium with, 1181
Obsessive-compulsive disorder (OCD)
clomipramine and, 908
cytokines and, 908
headache response to m-CPP in, 544
intranasal oxytocin in, 547
naloxone and, 154
smooth-pursuit eye movement and saccadic intrusions in, 1164
tridimensional personality questionnaire measures and, 271
tryptophan depletion and, 398
Obstetric complications
CT ventricular abnormality related to cycloid psychosis and, 1255
schizophrenia and, 1200
Oddball paradigm
single trial analysis of event-related potentials and, 844
Olfactory deficits
schizophrenia and, 1021
Ondansetron
alcohol intoxication and, 514
Opiates
P300 amplitude and, 617
Orbitofrontal integrity
schizophrenia and, 1021
Orgasm
spontaneous, with combined use of bupropion and sertraline, 1184-corr
Osmolality
chronic pain disorder and, 994
Osteoporosis
schizophrenia and, 430-corr
Overarousal
neural networks, 19
Oxytocin
intranasal, obsessive-compulsive disorder and, 547
intranasal, trichotillomania and-corr, 559

P2 amplitude
combat-related PTSD and, 373
P3 amplitude
asymmetry, schizotypal personality disorder and, 165
attention-deficit hyperactivity disorder and, 522
combat-related PTSD and, 373
P50 amplitude
schizophrenia and, 181, 1230
P300 amplitude
event-related potentials in schizophrenia and, 19
in opiate and cocaine users, 617
single trial analysis of event-related potentials and, 844
suicidal behavior in depression and, 116
Pallidoluysian atrophy
schizophrenia and, 228
Panic attacks
acute tryptophan depletion and, 648
inositol-induced anxiety and, 426
Panic disorder
clonazapam and, 913
cocaine and, 938

cyclic alternating pattern of sleep EEG in, 225
high-energy phosphate metabolism in frontal lobes and, 785
remitted, stress response and, 353
sleep, cholesterol levels and, 1064
Parietal frontal cortex
anorexia nervosa and, 761
cranial blood flow after cocaine hydrochloride and, 609
Parkinson's disease
fenfluramine and, 769
Paroxetine
glucocorticoids and serotonin transporter, 576
stress response in remitted panic disorder and, 353
tridimensional personality questionnaire measures and, 271
Patient Global Impression Scale
fluoxetine vs. phenelzine in atypical depression and, 1017
Peptide YY (PYY)
PCP and, 1246
Perinatal brain damage
cycloid psychosis and, 1255
Peripheral blood lymphocytes
D2-like dopamine receptors and, 881
Perseverance
and CSF 5-HIAA and testosterone, 1067
Persian Gulf syndrome
environmental chemical odor intolerance and, 123
Phencyclidine (PCP)
analogue, sensory gating and, 744
neuropeptide Y and peptide YY levels in rat brain and, 1246
Phenelzine
vs. fluoxetine, atypical depression and, 1017
Phenotype
seasonal affective disorder and, 1267
Phosphate metabolism
high-energy, panic disorder and, 785
Phosphocholine
proton MRS of basal ganglia in schizophrenia and, 14
Phospholipase C-β1
inositol 1,4,5-triphosphate binding in alcoholism and, 886
Phosphomonoester concentrations
lithium and, 235
Phototherapy
delayed sleep phase syndrome and, 794
sleep EEG in seasonal affective disorder and, 485
thyroid hormones in nonseasonal affective disorders and, 899
Physical stimulation
and spontaneous orgasm with combined use of bupropion and sertraline, 1184-corr
Physostigmine
HPA axis in Alzheimer's disease and, 61
Pimozide
prolactin monitoring of, Tourette's syndrome and, 1044
Pituitary-adrenal cortical axis function
adrenal gland volume in major depression and, 89
Plasma
β-endorphin, environmental chemical odor intolerance and, 134
dim-light melatonin onset in rapid cycling bipolar disorder and, 731
gamma-aminobutyric acid, Alzheimer's disease and, 933
homovanillic acid, anxiety and, 247
homovanillic acid, schizophrenia and, 1218
prolactin, Tourette's syndrome and, 1044
serotonin, clomipramine and, 465
Platelets
in alcoholism, inositol 1,4,5-triphosphate and, 886
monoamines, in bulimia nervosa and suicidality, 173
seasonal variability in 3H-imipramine and, 981
serotonergic markers, tridimensional personality questionnaire measures and, 271
Platform technique
REM sleep deprivation and, 1000
Point-Subtraction Aggression Paradigm
prolactin response to d-fenfluramine and, 157
Poisson regression analysis
schizophrenia and, 817
Polydiagnostic approach
CT ventricular abnormality related to cycloid psychosis and, 1255
Polydipsia
water intoxication and, 28
Polymerase chain reaction (PCR)
D2-like dopamine receptors and, 881, 1209
neuroleptic malignant syndrome and, 72
Polymorphisms
cytochrome P-450 2D6, 72
dopamine receptor gene, 144, 776, 1209
insertion/deletion, affective disorders and, 1122
seasonal affective disorder and, 1267
Polysomnography
environmental chemical odor intolerance and, 123
narcolepsy and, 208
panic disorder and, 225
Population attributable risk fraction
schizophrenia and, 817
Positive and Negative Syndrome Scale
schizophrenia and, 1021
Positive symptoms
schizophrenia and, 1209
Positron emission tomography (PET)
anorexia nervosa and, 761
attention-deficit hyperactivity disorder and, 951
memory in detoxified alcoholics and, 43
transient emotion and, 859
Post-lumbar-puncture headache
menstrual cycle and, 310-corr
Postmenopause
major depression and, 403
Postmortem brain
Alzheimer's disease and, 422
insertion/deletion polymorphism in angiotensin converting enzyme gene and, 1122
manganese-superoxide dismutase and, 230

protein kinase C in bipolar disorder and, 568
Posttraumatic stress disorder (PTSD)
combat-related, event-related potentials and, 373
cortisol in, 79
dopamine D2 receptor gene and, 368
prolactin response to dexamethasone challenge in combat veterans with, 1100
Postural syncope
autoregulation of cerebral blood flow and, 923
Preference
psychostimulant, 776
Prefrontal cortex
Borna disease virus-infected rats and, 629
medial, popaminergic drugs and, 1083
schizophrenia and, 1191
transient emotion and, 859
Prefrontal-temporal-limbic circuitry disorder
schizophrenia as, 585
Pregnancy
CT ventricular abnormality related to cycloid psychosis and, 1255
fetal malnutrition, schizophrenia and, 1-ed
influenza exposure during, schizophrenia, 817
Premenopause
major depression and, 403
Prenatal fetal developtment
influenza exposure during, schizophrenia and, 817
Prepulse facilitation
dizocilpine and, 744
Prepulse inhibition
dizocilpine and, 744
Profile analysis
functional brain imaging and, 1106
Progesterone
mood disorders and, 1051
Prolactin
acute tryptophan depletion and, 648
aggression and, 157
dexamethasone challenge in combat veterans with and without PTSD and, 1100
ECT and, 403
fenfluramine in Parkinson's disease and, 769
monitoring, of haloperidol and pimozide in Tourette's syndrome, 1044
TRH and, 403
Propranolol
akathisia and, 798
Protein changes
schizophrenic twins and, 437
Protein kinase C (PKC)
translocation in bipolar disorder in, 568
Psychogenic stress
biobehavioral consequences of, 317
Psychological stressors
mild, stress response in remitted panic disorder and, 353
Psychomotor disturbance
depression and, 941
Psychosis
APOE ϵ4 and, 1008
clozapine-chlorpromazine allergic cross-reactivity in AIDS and, 1186-corr
clozapine in, 253
cycloid, ventricular, 1255
manganese-superoxide dismutase and, 230
organic, linked to chronic tonsillitis and subsequent encephalitis, 292
Psychostimulant preference
dopamine D2 receptor and, 776
Pulse rate
cranial blood flow after cocaine hydrochloride and, 609

Quantitative autoradiographic assay
frontal cortical dopamine D1 receptors and, 1191
Quantitative electroencephalogram (QEEG)
children with attention-deficit hyperactivity disorder and, 951
crack cocaine dependence and, 986

Rapid-cycling bipolar disorder
choline and, 382
dim-light melatonin onset and, 731
self-report mania rating scales and, 279
Rapid eye movement (REM)
latency, schizophrenia and, 660, 927
sleep, transfer properties in depression and, 736
sleep behavior disorder, autopsy-confirmed Alzheimer's disease and, 422
sleep deprivation, serotonin reuptake blockers and, 1000
sleep disturbance, environmental chemical odor intolerance and, 123
Rating scales
d-amphetamine challenge and, 872
mania and, 279
Ratioing method
functional brain imaging and, 1106
Rearing experience
biogenic amine activity and, 338
Receptors
adenosine A_1, 563
benzodiazepine, peripheral-type, 221
B_2-, 203
cholecystokinin B, 550
dopamine, 419
dopamine D1, 1191
dopamine D2, 144, 368, 776, 881, 1209
inositol 1,4,5-triphosphate, 886
NMDA, 1298
NMDA-PCP, 1246
serotonin, 648
Recognition
abnormal, of facial expression, 697
Recurrence
depression, neurovegetative symptoms and, 691
Reflective cognitive operations
memory in detoxified alcoholics and, 43

Refractory depression
bromocriptine in, 151
Regressions
functional brain imaging and, 1106
Relapse
depression, neurovegetative symptoms and, 691
"Relaxed" conditions
schizophrenia and, 597
Remission
panic disorder and, 353
Renin-angiotensin system
chronic pain disorder and, 994
Resistant depression
imipramine with lithium for, 1181
Rest-activity rhythm disturbances
Alzheimer's disease and, 259
Restriction fragment length polymorphism (RFLP)
psychostimulant preference and, 776
schizophrenia and, 1209
tyrosine hydroxylase, unipolar depression and, 305
Rest state
transient emotion and, 859
Retardation
of conditioning to stimulus, latent inhibition paradigm and, 1083
Reverse-transcription PCR
D2-like dopamine receptors and, 881
Rhesus monkeys
and CSF 5-HIAA and testosterone, 1067
early experience and biogenic amine activity in, 338
Rhythmic finger tapping task
schizophrenia and, 1301
Right hemifield of vision
abnormal recognition of facial expression and, 697
Right hemisphere functions
depression and, 1282
Risk factors
cholesterol-lowering therapies and, 686-corr
Risk markers
schizophrenia and, 817, 825
Risperidone
schizophrenia and, 1056
RNA
D2-like dopamine receptors and, 881
Rorschach test
schizotypal personality disorder and, 853

Saccadic intrusions
obsessive-compulsive disrder and, 1164
smooth pursuit eye movements and, 1144
Sadness
self-induced, gender and, 859
Saliva
dim-light melatonin onset in rapid cycling bipolar disorder and, 731
flow rate, clozapine and, 1132
[^{H}]-SCH 23390
schizophrenia and, 1191
Schizophrenia
abnormal recognition of facial expression in, 697
anxiety in, 597
backward masking in, 295
blink rate in, 597, 1222
caffeine in, 1218
childhood-onset, 1222
clozapine in, 181, 542, 671, 834, 1056, 1222
cognitive function in, 434-corr D-cycloserine in, 1298
cytokines in, 1294
cytosine adenine guanine trinucleotide repeat in, 228
in Denmark, 817
dexamethasone nonsuppression in, 660, 927
diet in, 1218
dizocilpine in, 744
dopamine receptor genes in, 419
dopamine receptors in, 881
dopamine system in, 295, 597
dual energy X-ray absorptiometry in, 430-corr
EEG in, 452
evaluation of clinical symptoms in, 755
event-related potentials in, 19, 189
extrapyramidal side effects in, 604
facial expression in, 556
famine and, 1-ed
fast segmentation of neural processing in, 1301
fluorodeoxyglucose in, 443
fluvoxamine in, 75, 671
40-Hz activity in, 1301
gating of auditory P50 in, 181
glutamate in, 1298
glycine therapy in, 684-corr, 685-corr (response), 1298
gray matter deficits in, 4
hallucinations in, 597
haloperidol in, 604, 1135
hemispheric asymmetry in, 299
homovanillic acid in, 247, 1218
HPA axis in, 560-corr, 561-corr (response)
hygiene deficits in, 1021
increased head circumference in, 1173
insertion/deletion polymorphism in angiotensin converting enzyme gene in, 1122
latent inhibition model of, 834, 1135
local application of dopaminergic drugs into medial prefrontal cortex in, 1083
lorazepam in, 1218
magnetic resonance imaging in, 585
magnetoencephalography in, 299
melatonin in, 75
memory in, 299
α1-microglobulin in, 800
negative symptoms in, 597, 930, 1021, 1298
neurocognitive impairments in, 597
neuroleptics in, 597
neurological soft signs in, 1056
nicotine in, 1218
obstetric complications in, 1200

olfactory deficits in, 1021
osteoporosis in, 430-corr
polydipsia in, 28
polymorphisms of dopamine D2-like receptors in, 1209
postmortem study of frontal cortical dopamine D1 receptors in, 1191
prefrontal cortex in Borna disease virus rats and, 629
as prefrontal-temporal-limbic circuitry disorder, 585
proton MRS of basal ganglia in, 14
REM latency in, 660
rhythmic finger-tapping task in, 1301
risk and disease markers for, 825
risk factors for, 817
risperidone in, 1056
selective serotonin reuptake inhibitors in, 671
semantic matching of pictures in, 189
sensory gating in, 1230
Seroquel in, 434-corr
serum cholesterol in, 542
short rapid eye movement latency in, 927
single trial analysis of event-related potentials in, 844
spatial working memory deficits in, 930
substance abuse in onset of, 1155
temporal binding in, 1301
time perception in, 1301
transcranial magnetic stimulation in, 148
treatment-resistant, 542
in twins, 437
ulinastatin in, 800
verbal memory performance in, 443
water intoxication in, 28
Schizotypal personality disorder
information processing in, 853
P3 asymmetry and, 165
Seasonal affective disorder (SAD)
amino acid substitutions of 5-HT_{2A} receptor and, 1267
Seasonal variability
blood platelet 3H-imipramine binding and, 981
Second trimester
beri beri, schizophrenia and, 1-ed
Seizures
caffeine-augmented ECT and, 642
ECT effect on thalamic auditory potential and, 807
Selectivity of attention
haloperidol and, 1135
Self-care
schizophrenia and, 1021
Self-reporting
environmental chemical odor intolerance, 123, 134
mania and, 279
transient emotion and, 859
Self-Report Manic Inventory
evaluation of, 279
Semantic matching
of pictures, schizophrenia and, 189
Sensitization
cortisol release in major depression and PTSD, 79
environmental chemical odor intolerance and, 134
Sensory gating
CA3 neural network of hippocampus and, 1230
dizocilpine and, 744
schizophrenia and, 181, 1230
Septal inputs
sensory gating in schizophrenia and, 1230
Seroquel
schizophrenia and, 434-corr
Serotonin
acute tryptophan depletion and, 648
aggression and, 157
borderline personality and, 508
clomipramine and, 465
fenfluramine in Parkinson's disease and, 769
platelet dense granule secretion and, 892
slow-wave sleep deprivation and, 664
stress response in remitted panic disorder and, 353
tridimensional personality questionnaire measures and, 271
tryptophan depletion in obsessive-compulsive disorder and, 398
Serotonin-specific reuptake inhibitors (SSRIs)
akathisia and, 798
REM sleep deprivation and, 1000
schizophrenia and, 671
spontaneous orgasm and, 1184-corr
tolerance development to, 75
Sertraline
bupropion with, spontaneous orgasm and, 1184-corr
Sex steroids
inositol monophosphatase activity and, 656
Sexual dysfunction
serotonin reuptake inhibitors and, 1184-corr
Short-term memory
schizophrenia and, 299
Shyness
environmental chemical odor intolerance and, 123
Sialorrhea
clozapine and, 1132
Siblings
schizophrenia and, 825
Signal transduction
platelet dense granule secretion and, 892
Simvastatin
cholestokinin-tetrapeptide and, 302
Single photon emission computed tomography (SPECT)
functional brain imaging and, 1106
Single-strand conformational polymorphism analysis
dopamine D2-like receptors in schizophrenia and, 1209
seasonal affective disorder and, 1267
Single trial analysis
in depression and schizophrenia, 844
Sleep
adolescent depression and, 474
atypical depression and, 691
behavior disorder, Alzheimer's disease and, 422
in depression, transfer properties and, 736

deprivation, serotonin and melatonin profiles in, 664
deprivation, sleep EEG in seasonal affective disorder and, 485
disturbance, in cacosmic elderly, 123
EEG, cyclic alternating pattern of in panic disorder, 225
EEG, seasonal affective disorder and, 485
panic, cholesterol levels and, 1064
schizophrenia and, 660
Sleep-onset rapid eye movement periods (SOREMPS)
narcolepsy and, 208
Sleep-wake cycle
delayed sleep phase syndrome and, 794
Slow-wave sleep
deprivation, serotonin and melatonin profiles in, 664
Small effect genes
behavior and, 313-ed
Smoking
chronic pain disorder and, 994
monoamine oxidase and, 433-corr
obsessive-compulsive disorder and, 1164
Smooth-pursuit eye movement
childhood-onset schizophrenia and, 1144
obsessive-compulsive disorder and, 1164
Social deficit symptoms
schizotypal personality disorder and, 853
Social dominance behaviors
and CSF 5-HIAA and testosterone, 1067
Social isolation
neuropsychiatric disorders and, 918
Social stress
biobehavioral correlates of, 317
Society of Biological Psychiatry Executive Council Meeting
May 1, 1996, 1311
Somatostatin
ECT and, 54
Source monitoring
memory in detoxified alcoholics and, 43
Soy diet
environmental chemical odor intolerance and, 123
Spatial working memory deficits
negative symptoms in schizophrenia and, 930
Spectrum
schizophrenia, 853
Speech
d-amphetamine challenge and, 872
Stability
neurovegetative symptoms and, 691
Starvation
anorexia nervosa and, 761
Statistical analysis
functional brain imaging and, 1106
Stereology
hippocampal hilar somatostatinergic neurons after ECT and, 54
Stereoselectivity
D2-like dopamine receptors and, 881
Stereotypy
prefrontal cortex in Borna disease virus rats and, 629
Stimulus deviancy
attention-deficit hyperactivity disorder and, 522
Stress response
chronic pain disorder and, 994
homovanillic acid and, 247
nocturnal growth hormone secretion in depressed children and, 1176
rearing experience and biogenic amine activity, 338
remitted panic patients and, 353
social, biobehavioral correlates of, 317
social isolation and, 918
Striatum
caffeine-augmented ECT and, 642
PCP and, 1246
Stroke
depression in chronic vasculopathic patients and, 637
Structured Clinical Interview
atypical depression and, 691
Strychnine
NMDA receptor and, 1298
Study dropouts
difference of from completers, 668
Subarachnoid region
hippocampal volume in combat-related PTSD and, 1091
Subcortical structures
attention-deficit hyperactivity disorder and, 951
Substance abuse
in African Americans, dopamine D2 receptor gene polymorphisms and, 144
D2 dopamine receptor gene *Taq*I A1 and B1 restriction fragment length polymorphisms and, 776
euthyroid sick syndrome among psychiatric inpatients and, 1288
obsessive-compulsive disorder and, 1164
platelet dense granule secretion and, 892
schizophrenia onset and, 1155
Substance P
insertion/deletion polymorphism in angiotensin-converting enzyme gene and, 1122
Substantia nigra
bipolar disorder and, 726
compulsion and, 726
dystonia and, 726
insertion/deletion polymorphism in angiotensin-converting enzyme gene and, 1122
Suicidality
borderline personality disorder and, 173
depression and, 116
EEG alpha asymmetry in female suicide attempters, 706
Suicides
frontal cortical dopamine D1 receptors and, 1191
Sulcal spaces
schizophrenia and, 1200
Sulpiride
D2-like dopamine receptors and, 881
Superior frontal cortex

anorexia nervosa and, 761
Suprachiasmatic nucleus
Alzheimer's disease and, 259
Sweden
schizophrenia and, 228
Synaptosomes
glucocorticoids and serotonin transporter, 576

Tacrolimus
side effects and, 407
*Taq*I A1 and B1 restriction fragment length polymorphisms
D2 dopamine receptor gene, psychostimulant preference and, 776
Tardive dyskinesia
handedness and, 35
Task relevance
attention-deficit hyperactivity disorder and, 522
T-cells
suppressor/cytotoxic, depression and, 1273
Temporal binding
schizophrenia and, 1301
Temporal cortex
transient emotion and, 859
Temporal lobes
MRI in schizophrenia and, 585
Ten commandments
of psychiatric research, 675
Tension
cranial blood flow after cocaine hydrochloride and, 609
Testosterone
CSF, aggressive behavior and, 1067
Tetradecanoyl phorbol acetate
TIS gene induction and, 503
Thalamus
electroconvulsive shock and, 807
Thrombin
platelet dense granule secretion and, 892
Thyroid hormones
euthyroid sick syndrome among psychiatric inpatients and, 1288
major depression and, 428
Thyroid-stimulating hormone (TSH)
depression in chronic vasculopathic patients and, 637
euthyroid sick syndrome among psychiatric inpatients and, 1288
Thyrotropin (TSH)
ECT and, 403
elevated, dementia and, 714
nonseasonal affective disorders and, 899
TRH and, 403
Thyrotropin-releasing hormone (TRH)
borderline personality disorder and, 412
depression in chronic vasculopathic patients and, 637
Thyroxine (T_4)
euthyroid sick syndrome among psychiatric inpatients and, 1288
nonseasonal affective disorders and, 899
Tic
Tourette's syundrome and, 1044
Time-dependent sensitization
environmental chemical odor intolerance and, 134
Time perception
depressive psychomotor disturbance and, 941
schizophrenia and, 1301
TIS genes
ECS-induced, 503
Tone presentation
clozapine in schizophrenia and, 834
Tonsillitis
chronic, organic psychosis and, 292
Total sleep deprivation
sleep EEG in seasonal affective disorder and, 485
Transcranial magnetic stimulation (TMS)
in depression and schizophrenia, 148
Transfer metabolites
CSF, atmospheric pressure and, 682-corr, 683-corr (response)
Transfer properties
sleep in depression and, 736
Transferrin
serum concentrations, major depressive disorder and, 1128
Transient emotion
gender and, 859
Translocation
protein kinase C, bipolar affective disorder and, 568
Transporter
serotonin, glucocorticoids and, 576
Treatment-resistant depression
bromocriptine in, 151
Trichotillomania
intranasal oxytocin in, 559-corr
Tricyclic antidepressants
depression resistant to, bromocriptine in, 151
lithium with, 1181
musical hallucinations and, 309-corr, 310-corr (response)
Tridimensional Personality Questionnaire
platelet serotonergic markers and, 271
Triglycerides
serum concentrations, major depressive disorder and, 1128
Triiodothyronine (T_3)
nonseasonal affective disorders and, 899
Trimethylamine
proton MRS of basal ganglia in schizophrenia and, 14
Tryptophan
depletion, effects of, 648
depletion, obsessive-compulsive disorder and, 398
Twins
schizophrenic, protein changes in, 437
Tyrosine
seasonal affective disorder and, 1267
Tyrosine hydroxylase
dopamine-related genes and, 1032
RFLP, unipolar depression and, 305

Ulinastatin
urinary α1-microglobulin and, 800

Unidirectional causality
substance abuse and schizophrenia, 1155
Unipolar depression
atypical, neurovegetative symptoms and, 691
tyrosine hydroxylase RFLP in, 305
University of Pennsylvania Smell Identification Test
schizophrenia and, 1021
Urine
epinephrine, during intelligence testing in attention-deficit hyperactivity disorder boys, 553
homovanillic acid, schizophrenia and, 1218

Valine
seasonal affective disorder and, 1267
Vasculopathic patients
nondepressed, neuroendocrine anomalies in, 637
Ventricular abnormality
cycloid psychosis and, 1255
Ventricular/brain ratio
hippocampal volume in combat-related PTSD and, 1091
smooth pursuit eye movements and, 1144
Ventricular size
schizophrenia and, 1200
Ventricular spaces
schizophrenia and, 1200
Verbal memory performance
schizophrenia and, 443
Vietnam veterans
hippocampal volume in PTSD and, 1091
Violent behavior
and CSF 5-HIAA and testosterone, 1067
Viruses
schizophrenia and, 629
Visual Analogue Scale
and spontaneous orgasm with combined use of bupropion and sertraline, 1184-corr
tryptophan depletion in obsessive-compulsive disorder and, 398
Visual backward masking
schizotypal personality disorder and, 853
Visual event-related potentials
acute alcohol effect and, 284
combat-related PTSD and, 373
transfer properties in depression and, 736
Visual paradigms
haloperidol and, 1135
Volume
adrenal gland, major depression and, 89
hippocampal, in combat-related PTSD, 1091
Vulnerability
dopamine D2-like receptors in schizophrenia and, 1209
substance abuse in African Americans and, 144
35% carbon dioxide, panic disorder and, 913
Vulnerability markers
schizophrenia and, 825

Water intoxication
polydipsia and, 28
Wechsler Memory Scale—Revised
schizophrenia and, 1021
White matter
MRI in schizophrenia and, 585
Whole brain volume
hippocampal volume in combat-related PTSD and, 1091
Wounding behavior
and CSF 5-HIAA and testosterone, 1067

X chromosome
infantile autism and, 457
^{133}Xe single photon emission computed tomography
cranial blood flow after cocaine hydrochloride and, 609
functional brain imaging and, 1106
regional cerebral blood flow after haloperidol and, 604

Yawning
and spontaneous orgasm with combined use of bupropion and sertraline, 1184-corr
Young Mania Rating Scale
evaluation of, 279

Zinc deficiency
attention-deficit hyperactivity disorder and, 1308